

Curriculum Vitae

Robert S. Sandler, M.D., M.P.H.

PERSONAL INFORMATION

Home Address 2616 Creek Ridge Lane
Chapel Hill, North Carolina 27514

Business Address CB# 7555, 4157 Bioinformatics Building
Division of Gastroenterology and Hepatology
Department of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 27599-7080
(919) 966-0090
FAX (919) 966-7592
email rsandler@med.unc.edu

Spouse Dale P. Sandler, Ph.D.
Chief, Epidemiology Branch
National Institute of Environmental Health Sciences
Research Triangle Park, NC

Children David James (June 7, 1981)
Michael Adam (April 30, 1986)

EDUCATION

MPH, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, 1980-82, epidemiology.
MD, Yale University School of Medicine, New Haven, Connecticut, 1971-75, medicine.
BS, Union College, Schenectady, New York, 1967-71, *summa cum laude*, biology

POSTGRADUATE TRAINING

Trainee in Cancer Epidemiology, Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 1980-82
NIH Clinical Cancer Fellow, North Carolina Memorial Hospital, Chapel Hill, NC, 1979-81
Research Fellow in Gastroenterology, Division of Digestive Diseases and Nutrition, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 1979-81
Fellow in Gastroenterology, Division of Digestive Diseases and Nutrition, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 1978-80
Resident in Internal Medicine, George Washington University Hospital, 901 23rd Street NW, Washington, DC, 1976-78
Intern in Internal Medicine, George Washington University Hospital, 901 23rd Street NW, Washington, DC, 1975-76

PROFESSIONAL EXPERIENCE

Nina C. and John T. Sessions Distinguished Professor of Medicine, University of North Carolina, 5/03-
Chief, Division of Gastroenterology and Hepatology, University of North Carolina, 1/03-
Professor of Epidemiology, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, 4/01-

Professor of Medicine, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, 7/95-
Clinical Professor of Epidemiology, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, 7/95-4/01
Clinical Associate Professor of Epidemiology, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, 7/88-7/95
Director, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, 1992-
Clinical Assistant Professor of Epidemiology, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, 7/83-7/88
Acting Director, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, 3/91-7/92
Assistant Professor of Medicine, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, 7/83-7/88
Associate Professor of Medicine, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, 7/88-7/95
Associate Director, Core Center in Diarrheal Diseases, University of North Carolina, Chapel Hill, NC, 9/85-11/89
Instructor of Medicine, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, 7/82-6/83
Clinical Instructor of Epidemiology, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, 7/82-6/83
Clinical Instructor of Medicine, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, 7/81-7/82

BOARD CERTIFICATION

National Board of Medical Examiners, July 1, 1976, No. 159,284
American Board of Internal Medicine, September 13, 1979, No. 63980
American Board of Gastroenterology, November 10, 1981, No. 63980

MEDICAL LICENSURE

North Carolina, #22821, 1978
Washington, DC, 1975

PROFESSIONAL SOCIETIES

American College of Gastroenterology, Fellow, 2008-
American Society for Gastrointestinal Endoscopy, 1993-
Gastroenterology Research Group, Member 1990-
American College of Epidemiology, Fellow, 1991-2000
American Federation for Clinical Research, Member, 1983-1992
American Society of Preventive Oncology, Member, 1982-
American College of Physicians, Fellow, 1982-2002
American Gastroenterological Association, Fellow, 1981-

HONORS AND AWARDS

Julius Friedenwald Medal, American Gastroenterological Association, May 20, 2015.
 Distinguished Mentor Award, American Gastroenterological Association, May 5, 2014.
 UNC Gastroenterology Fellows Award for Excellence in Mentoring, 2011-12, June 16, 2012
 AGA Institute Council Clinical Practice Section Research Mentor Award, May 19, 2012
 Advisory Committee, Gastroenterology, May 2011-16.
 10 Great Physicians in North Carolina. Beckers ACS Review. June 30, 2011
 UNC Gastroenterology Fellows Award for Excellence in Mentoring, 2010-11, June 18, 2011
 75 of the Best Gastroenterologists in America, Beckers ACS Review, November 12, 2010
 Outstanding Clinical Co-Mentor, Graduate Training Program in Translational Medicine, April 15, 2010.
 Wade Volwiler Visiting Professor, University of Washington, Seattle, WA, October 14-16, 2009.
 Arthur J. Atkinson, Sr. Lecture in Gastroenterology, Northwestern University, Chicago, IL, October 6, 2009
 Chair, American Gastroenterological Association, 2009-10
 UNC Gastroenterology Fellows Award for Excellence in Mentoring, 2008-109, June 13, 2009
 Ken and Louise Goldberg Visiting Professor, Brigham and Women's Hospital, Harvard Medical School, April 23, 2009
 Samuel D. Kushlan Visiting Professor. Yale University School of Medicine. New Haven, CT. February 20, 2008
 President, American Gastroenterological Association Institute, 2008-9.
 President-elect, American Gastroenterological Association Institute, 2007-8.
 Fellow, American College of Gastroenterology, 2007.
 Joseph B. Kirsner Visiting Scholar, University of Chicago, September 6, 2007.
 Nath Lecture, Massachusetts General Hospital, January 16, 2007.
 Fellow, American Gastroenterological Association, 2007
 Best Doctors in America, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014.
 Best Doctors in North Carolina, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014.
 Masters Award for Sustained Achievement in Digestive Disease May 2006
 Vice President, American Gastroenterological Association Institute, 2006-7
 Salmon Lecture, Vanderbilt University, Nashville TN, April 7, 2005
 Fifth Annual Hack Distinguished Speaker, Stanford University School of Medicine, Palo Alto, CA, March 24, 2004.
 Foundation for Digestive Health and Nutrition, Fitterman Foundation "Joseph B. Kirsner" Clinical Research Award in Gastroenterology, 2004
 Senior Research Fellow, Sheps Center for Health Services Research, 1997-2002.
 Pogue Competitive Research Leave, University of North Carolina, 1996
 UNC School of Public Health Alumni Conference Award, 1989
 Research Associates Award, National Foundation for Ileitis and Colitis, 1987
 Junior Faculty Fellowship, American Cancer Society, 1981
 Phi Beta Kappa, Union College, Schenectady, NY, 1971
 Nott Scholar, Union College, Schenectady, NY, 1970

PEER REVIEW ACTIVITIES

National Institutes of Diabetes and Digestive and Kidney Diseases, Ad Hoc Reviewer, December 17, 2013.
 National Institute of Diabetes and Digestive and Kidney Diseases, DDK-C, 2012-2016
 National Institute of Diabetes and Digestive and Kidney Diseases, DDK-C, Ad Hoc Reviewer, October 24-26, 2011
 National Institute of Diabetes and Digestive and Kidney Diseases, Ad Hoc Review Group ZDK1 GRB-C, 2009
 Crohn's and Colitis Foundation of America, Grant Review for CDC Epidemiology Grant Program, 2007
 Center for Scientific Review Special Emphasis Panel, National Institutes of Health, Ad Hoc Reviewer ARG1
 KNOD-N(01), 2006
 National Institute of Diabetes and Digestive and Kidney Diseases, Ad Hoc Review Group ZDK1 GRB-C, 2002
 Crohn's & Colitis Foundation of America, Grant Review Panel, 2000-2004
 American Digestive Health Foundation - Outcomes Research Scholar Award, 1992-1999
 Manuscripts reviewed for the following journals: Annals of Internal Medicine, Gastroenterology, American Journal of Epidemiology, New England Journal of Medicine, Journal of Clinical Epidemiology, Digestive Diseases and

Sciences, Journal of Clinical Gastroenterology, American Journal of Gastroenterology, Mayo Clinic Proceedings, Western Medical Journal, Journal of General Internal Medicine, Medical Care, Cancer Epidemiology Biomarkers and Prevention, Epidemiology, Croatian Medical Journal, Evidence-Based Gastroenterology, Inflammatory Bowel Diseases, Alimentary Pharmacology and Therapeutics, Clinical Gastroenterology and Hepatology, JAMA, International Journal of Inflammation
 Abstract selection committee (clinical epidemiology), American Gastroenterological Association, Chair, 1991, member 1999, chair 2000, member 2001
 National Cancer Institute, Site Visitor, 1991, 1989, 1988
 National Foundation for Ileitis and Colitis, Grant Review Committee (ad hoc) 1988
 Epidemiology and Disease Control - 2, NIH Study Section (ad hoc member), 1990
 Clinical Research Award Selection Committee, American Gastroenterological Association, 1992-1995, Chair
 AGA Foundation/Industry Research Scholar Selection Committee, American Gastroenterological Association, 1994-7.
 National Institute of Diabetes and Digestive and Kidney Diseases, Ad Hoc Review Group 5, 1992.
 National Institutes of Health, Epidemiology and Disease Control - 2 study section, member (1992-1996)
 National Institute of Diabetes and Digestive and Kidney Diseases, Ad Hoc Review, November 1999.

EDITORIAL BOARDS

Cancer Epidemiology Biomarkers and Prevention, 2003-6
 Gastroenterology, 2001-2006 (Associate Editor)
 Evidence-Based Gastroenterology, 2000-2008
 Inflammatory Bowel Diseases, 1995-2000
 International Journal of Gastroenterology, 1996- 2000

COMMITTEES

AGA Foundation, Chair, 2015-18
 Advisory Committee Harvard Digestive Disease Research Core Center, 2015-
 Distinguished Mentor Award Selection Committee, American Gastroenterological Association, 2015
 AGA Publications Committee, Chair, 2012-15
 Distinguished Achievement Award Selection Committee, American Gastroenterological Association, 2011
 AGA Nominating Committee, Chair, 2010-11
 AGA Audit Committee, 2010-11
 Advisory Committee, Texas Gulf Coast Digestive Disease Center, 2008-
 Steering Committee, MEDVAMC HSR&D Center of Excellence, Baylor College of Medicine, 2008-
 National Digestive Disease Commission, National Institutes of Health, 2006-7.
 AGA President 2008
 AGA President Elect 2007
 AGA Vice President, 2006
 AGA Executive Committee, 2006-9
 AGA NSAID consensus conference – American Gastroenterological Association, 2005
 AGA Outcomes Research Award Review Committee – American Gastroenterological Association, 2005
 Fiterman Foundation Awards Committee - American Gastroenterological Association, 2005.
 Futures Committee – American Gastroenterological Association, 2005-2008.
 AGA Representative GI Symposium Program Planning Committee – ASCO, AGA, ASTRO, SSO, 2005
 Distinguished Achievement Award Selection Committee, American Gastroenterological Association, 2005.
 Government Affairs Committee, Crohn's & Colitis Foundation of America, (chair) October 1, 2002-2005
 Research Policy Committee, American Gastroenterological Association, 2002-2005
 Texas Gulf Coast Digestive Disease Research Center, Scientific Advisory Committee, 2002-
 National Cancer Institute Stomach/Esophageal Cancers Progress Review Group Roundtable, member. 2002
 Digestive Sciences Study Section Boundary Team, Center for Scientific Review, National Institutes of Health, 2002.
 Burden of Disease Task Force, American Gastroenterological Association, 2000-2001.
 10-Year Research Agenda Task Force, American Gastroenterological Association, 2001

Membership and Diversity Council, American Gastroenterological Association, Chair, 2001-04
 Councilor-at-Large, Governing Board, American Gastroenterological Association, 2001-04
 Research & Training Task Group, Public Policy and Advocacy Committee, American Gastroenterological Association, 2001-
 Abstract review committee, American Gastroenterological Association, 1998,1999 (chair), 2000, 2001, 2002, 2003
 Trans NIDDK Strategic Planning Committee, NIDDK, National Institutes of Health, 2000-2001
 Public Policy and Advocacy Committee, American Gastroenterological Association, 2000-
 National Cancer Institute Colorectal Cancer Progress Review Group Roundtable, member. 2000
 GI Oncology Task Force, American Gastroenterological Association, 1999.
 Nominating Committee, American Gastroenterological Association, 1999-2000
 Outcomes Research Subcommittee - ADHF Research Policy Committee, Chair, 1997-99
 Research Policy Committee, American Digestive Health Foundation, 1996-99
 Liver Transplant Database, Policy Board, National Institutes of Health, NIDDK, 1995
 Outcomes Research Task Force, American Gastroenterological Association, chair, 1994 -1995
 Task Force on Research Goals, American Gastroenterological Association, 1994-96
 Research Committee, American Gastroenterological Association, 1992-1996.
 Task Force on Digestive Diseases and Nutrition, Program Planning Committee, UNC School of Medicine; acting chair, 1991 - 1994
 Council on Clinical Epidemiology, American Gastroenterological Association, Member, 1987-88
 IBD Forum Committee, Crohn's and Colitis Foundation of America, 1989-95
 National Digestive Diseases Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Member, 1987-94
 Policy and Data Monitoring Board, A Multicenter, Randomized Clinical Trial Comparing the Side Effects and Efficacy of Olsalazine Sodium and Sulfasalazine in the Treatment of Mild Ulcerative Colitis in Children, Member, 1987-89
 Safety and Data Monitoring Committee, Nutritional Prevention of Polyps of the Large Bowel (CA 37278), Member, 1986-88
 Breast Cancer Detection Awareness Task Force, North Carolina Division, American Cancer Society, Chair, 1986
 Professional Education Committee, North Carolina Division, American Cancer Society, Chair, 1984-88
 Public Education Committee, North Carolina Division, American Cancer Society, Member, 1983-84
 Colorectal Cancer Health Check Committee, North Carolina Division, American Cancer Society, Member, 1983-84

UNIVERSITY ACTIVITIES

Task Force on Quality, UNC School of Medicine Strategic Planning, 2012, chair
 Search Committee, Division of Hematology and Oncology, UNC, 2012, chair
 Search Committee, Division of Pulmonary Medicine, UNC, 2009
 Radiation Oncology Chair Search Committee, 2005-6., chair
 James Woods Junior Faculty Award and Jefferson-Pilot Fellowship Award committee 2005-9
 School of Medicine Non-Tenure Track Promotions Committee, 2002-8, chair
 Doctoral Committees – Departments of Epidemiology, Health Policy and Administration, Nutrition, Health Behavior and Education, Physiology
 Grant Reviewer – Lineberger Cancer Research Center, 1990, 1991, 1992, 1993, 1994, 1999, 2000, 2001
 Search Committees – Faculty for Departments of Epidemiology, Nutrition, Chief of Cardiology, Chair of Surgery
 Faculty Council, 1988-91
 Clinical Cancer Committee, 1989-90
 Committee on Faculty Research and Study Leaves, 1997-98
 Clinical Cancer Report, editor, 1990-92
 Member, Epidemiology Section, Lineberger Cancer Research Center, 1981-

RESEARCH SUPPORT

Current Funding as Principal Investigator

1. Risk factors for microscopic colitis. National Institutes of Health. R01 DK105114, 12/1/15-11/30/18,\$ 2,918,910.
2. Risk factors for asymptomatic diverticulosis. National Institutes of Health, R01DK094738, 4/1/12-2/31/17, \$2,150,326.
3. Digestive Disease Research Core Center (Center for Gastrointestinal Biology and Disease). National Institutes of Health P30 DK034987. 12/1/1996-11/30/2019, \$5,000,000
4. Digestive Disease Epidemiology Training Grant (renewal), National Institutes of Health, 2T32 DK07634, 7/1/14-6/30/19, \$1,157,815
5. SHARE Data Management Center, Helmsley Foundation, 2/1/12-1/31/17. \$2,382,187.
6. CCFA Partners – an Internet Cohort. Crohn’s and Colitis Foundation of America, 1/1/2011-12/31/2017. \$539,963
7. Data Management Center for the Clinical Alliance of the CCFA, Crohn’s and Colitis Foundation of America, 10/01/2006-9/30/2016; \$390,000

Past NIH Funding

1. Intestinal microbiota, inflammation and the risk of colorectal adenomas, National Institutes of Health. R01-CA136887, 05/01/2009-02/28/2015, \$1,250,000.
2. Cancer Care Outcomes Research and Surveillance Consortium, *Principal Investigator*, National Institutes of Health, U01 CA93326, 10/1/02-9/30/12, Total Direct Costs \$3,605,584.
3. Short Term Research Training, *Principal Investigator*, National Institutes of Health, T35DK007386, 5/1/00-8/31/15, Total Direct Costs \$871,895
4. Inflammation, obesity and the risk of colorectal adenomas. *Principal Investigator*, National Institutes of Health, R01 CA44684, 7/1/06-6/30/12, \$1,604,679.
5. Prognostic and predictive factors in colon cancer. *Principal Investigator*. Project 1, SPORE in Gastrointestinal Cancer, P50CA106991 (Tepper, PI), 6/1/04-5/31/09, \$193,002
6. Medical Student Scholars Program. *Principal Investigator*, National Institutes of Health, T32 DK062666, 09/30/2002 - 09/29/2007, Total Direct Costs \$387,000
7. Multi-site Trial of Azathioprine Dosing in Crohn’s Disease. *Director – Data Center*. NIH , U01DK060083 7/03-4/08. \$183,732
8. Population Study of Colon Cancer in Blacks and Whites, *Principal Investigator*, National Institutes of Health, R01CA66635, 7/1/01/01-6/30/07, Total Direct Costs \$2,892,812
9. Epidemiology of Rectal Mucosal Proliferation, *Principal Investigator*, National Institutes of Health, R01 CA44684, 4/1/01-1/31/04 (renewal), Total Direct Costs \$1,052,724.
10. Center for Gastrointestinal Biology and Disease (renewal), *Principal Investigator*, National Institutes of Health P30 DK34987, 12/1/00-11/30/14, Total Direct Costs \$15,000,000
11. Barrett’s Esophagus Surveillance Trial (BEST), *Principal Investigator*, National Institutes of Health. R03 KD56748, 4/1/00-3/31/02, Total Direct Costs \$106,390
12. Digestive Disease Epidemiology Training Grant (renewal), *Principal Investigator*, National Institutes of Health, T32 DK07634, 7/1/99-6/30/04, Total Direct Costs \$558,550
13. Calcium Prevention of Colon Polyps (renewal), *Principal Investigator* (N.C. Subcenter), National Cancer Institute, U01 CA46917, 1/99-12/03, total direct costs \$ 1,117,132
14. Aspirin/Folate Prevention of Neoplastic Polyps, *Principal Investigator* (N.C. Subcenter), National Cancer Institute, R01 CA59005, 12/01/98-07/31/07, total direct costs \$909,653.
15. Epidemiology of Rectal Mucosal Proliferation, *Principal Investigator*, National Institutes of Health, R01 CA44684, 4/1/98-1/31/01, Total Direct Costs \$898,405.
16. Colorectal Cancer Family Registry, *Principal Investigator* (N.C. Subcenter), National Cancer Institute, U01-CA74799, 12/1/97-11/30/02, Total Direct Costs \$1,090,109.
17. Population Study of Colon Cancer in Blacks and Whites, *Principal Investigator*, National Institutes of Health, R01CA66635, 7/1/96-6/30/01, Total Direct Costs \$2,021,031.
18. Digestive Disease Epidemiology Training Grant (renewal), *Principal Investigator*, National Institutes of Health, T32 DK07634, 7/94-6/99, Total Direct Costs \$499,998

19. Center for Gastrointestinal Biology and Disease (renewal), *Principal Investigator*, National Institutes of Health P30 DK34987, 12/1/94-11/30/99, Total Direct Costs \$3,310,328
20. Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study, *Principal Investigator*, National Institutes of Health (NCI - through CALGB), 3/1/93 - 2/28/94.
21. Epidemiology of Rectal Mucosal Proliferation, *Principal Investigator*, National Institutes of Health, R01 CA44684, 2/1/92-1/31/97, Total Direct Costs \$800,254.
22. Center for Gastrointestinal Biology and Disease, *Principal Investigator*, National Institutes of Health, P30 DK34987, 12/1/89-11/30/94, Total Direct Costs \$2,592,794.
23. Fatty Acid Exposure and Risk of Prostate Cancer, *Co-investigator*, National Institutes of Health, R01 CA55760, 12/1/91 - 11/30/95, Total Direct Costs \$1,098,756.
24. Digestive Disease Epidemiology Training Grant, *Principal Investigator*, National Institutes of Health, T32 DK07634, 7/90-6/94, Total Direct Costs \$224,224.
25. Calcium Prevention of Colon Polyps, *Principal Investigator* (N.C. Subcenter), National Cancer Institute, U01 CA46917, 9/88-8/93, Total Costs \$241,225.
26. Risk factors for Colon Adenomas, *Principal Investigator*, National Cancer Institute, R01 CA44684, 6/88-5/92, Total Direct Costs \$390,586.
27. Irritable Bowel Syndrome: Characterizing the Patient, *Co-Investigator*, National Institutes of Health, R01 AM29934, 4/83-4/85, Total Direct Costs \$345,136.
28. Preventive Oncology Academic Award, *Principal Investigator*, National Institutes of Health K07 CA 00722, 5/82-8/85, Total Direct Costs \$255,743.

PAST FUNDING OTHER

1. Improving use of surveillance colonoscopy: a pilot study. UNC Lineberger Development Grant. 7/1/12-6/30/13. \$40-,000
2. Study to Determine the Effect of 156 Weeks of Treatment with MK0966 on the Recurrence of Colorectal Adenomas. *Principal Investigator*. Merck. 5/1/00-4/30/06, \$1,634,960
3. Data Management Center, Clinical Alliance, *Principal Investigator*, Crohn's & Colitis Foundation of America. 9/99-9/06, \$640,000.
4. Colorectal Cancer Risk Factors for Advanced Disease, *Director, Data Center*. US Department of Veterans Affairs V558P-3396. 7/99-9/01. \$454,394.
5. The Risk of Esophageal Cancer in Patients with Achalasia: a population-based study, *Principal Investigator*, American Society for Gastrointestinal Endoscopy, 12/93-11/94, \$6,600.
6. Sulfates in Drinking Water, *Principal Investigator*, Environmental Protection Agency, 10/92-9/94, \$150,000
7. Computerized Gastrointestinal Endoscopy Data System, *Principal Investigator*, University of North Carolina Hospitals Innovative Projects Program, 7/90-6/91, \$14,600
8. Rectal Mucosal Ornithine Decarboxylase Activity and Colon Adenomas, *Principal Investigator*, Core Center in Diarrheal Diseases, University of North Carolina, 12/88-12/89, \$6,000
9. Epidemiology of Inflammatory Bowel Disease, *Principal Investigator*, National Foundation for Ileitis and Colitis, 1/86-12/87, Total Direct Costs \$97,211.
10. Epidemiology of Inflammatory Bowel Disease, *Principal Investigator*, Core Center in Diarrheal Diseases, University of North Carolina, 9/85-8/87, Total Direct Costs \$18,100.
11. Enhancing Colon Cancer Screening in High Risk Siblings, *Principal Investigator*, American Cancer Society #PBR-10A, 1/86-12/87, Total Direct Costs \$45,000 (competitive renewal).
12. Double-blind, Placebo-Controlled Multicenter Evaluation of Dextromethorphan for Relief of Abdominal Pain of Irritable Bowel Syndrome, Nelson Research and Development Company, Irvine, CA, 9/85-8/87, \$37,615.
13. Enhancing Colon Cancer Screening in High Risk Siblings, *Principal Investigator*, American Cancer Society #PBR-10, 1/84-12/85, Total Direct Costs \$96,000.
14. Patient Use of HEMATEST, Miles Laboratories, Ames, Iowa, 6/82-9/82, \$3,500.
15. Junior Faculty Clinical Fellowship, American Cancer Society, JCF 629, 7/81-7/84, \$27,000.
16. Medical Faculty Grant Award, University of North Carolina, 3/80-3/81, \$2,000.

PUBLICATIONS

Refereed Journals

1. **Sandler RS.** Beta error vs. nonsignificant significance. *Gastroenterology* 1980;78:1119-20
2. Kinard HB, 3rd, Powell DW, **Sandler RS**, Callahan WT, Lapis JL, Levinson SL, Jones JD, Drossman DA, Jackson AL. A current approach to acute upper gastrointestinal bleeding. *J Clin Gastroenterol* 1981;3:231-40
3. Lipper S, Kahn LB, **Sandler RS**, Varma V. Multiple juvenile polyposis. A study of the pathogenesis of juvenile polyps and their relationship to colonic adenomas. *Hum Pathol* 1981;12:804-13
4. Nuzum CT, **Sandler RS**, Paulk HT. Thrombocytosis in Whipple's disease. *Gastroenterology* 1981;80:1465-7
5. **Sandler RS**, Lipper S. Multiple adenomas in juvenile polyposis. *Am J Gastroenterol* 1981;75:361-6
6. **Sandler RS**, Sartor RB, Bozyski EM. Endoscopic appearance of cancer metastatic to the stomach. *J Clin Gastroenterol* 1981;3 Suppl 1:35-7
7. **Sandler RS**, Wood DR, Bozyski EM. Endoscopic removal of a granular cell tumor of the esophagus. *Gastrointest Endosc* 1981;27:70-2
8. Drossman DA, **Sandler RS**, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. *Gastroenterology* 1982;83:529-34
9. **Sandler RS**, Bozyski EM, Orlando RC. Failure of clinical criteria to distinguish between primary achalasia and achalasia secondary to tumor. *Dig Dis Sci* 1982;27:209-13
10. **Sandler RS**, Varma V, Herbst CA, Jr., Montana GS, Rudnick SA, Fowler WC, Jr. Use of the flexible sigmoidoscope in women with previous pelvic irradiation. *Gastrointest Endosc* 1982;28:237-9
11. Everson RB, Flack PM, **Sandler RS**. Urinary excretion of mutagens in cirrhosis: limited evidence of an association. *Environ Res* 1983;32:118-26
12. Sandler DP, **Sandler RS**, Horney LF. Primary liver cancer mortality in the United States. *J Chronic Dis* 1983;36:227-36
13. **Sandler RS**. Diet and cancer: food additives, coffee, and alcohol. *Nutr Cancer* 1983;4:273-9
14. **Sandler RS**, Sandler DP. Radiation-induced cancers of the colon and rectum: assessing the risk. *Gastroenterology* 1983;84:51-7
15. Hak LJ, Raasch RH, Hammer VB, Matthews T, **Sandler RS**, Heizer WD. Comparison of intravenous glucose and fat calories on host and tumor growth. *JPEN J Parenter Enteral Nutr* 1984;8:657-9
16. Metzgar RS, Rodriguez N, Finn OJ, Lan MS, Daasch VN, Fernsten PD, Meyers WC, Sindelar WF, **Sandler RS**, Seigler HF. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. *Proc Natl Acad Sci U S A* 1984;81:5242-6 391674.
17. **Sandler RS**. Has primary gastric lymphoma become more common? *J Clin Gastroenterol* 1984;6:101-7
18. **Sandler RS**. Primary gastric lymphoma: a review. *Am J Gastroenterol* 1984;79:21-5
19. **Sandler RS**, Drossman DA, Nathan HP, McKee DC. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. *Gastroenterology* 1984;87:314-8
20. **Sandler RS**, Freund DA, Herbst CA, Jr., Sandler DP. Cost effectiveness of postoperative carcinoembryonic antigen monitoring in colorectal cancer. *Cancer* 1984;53:193-8
21. **Sandler RS**, Johnson MD, Holland KL. Risk of stomach cancer after gastric surgery for benign conditions. A case-control study. *Dig Dis Sci* 1984;29:703-8
22. Drossman DA, **Sandler RS**, Broom CM, McKee DC. Urgency and fecal soiling in people with bowel dysfunction. *Dig Dis Sci* 1986;31:1221-5
23. Mehta SR, **Sandler RS**, Ford RJ, Sharma S, Maizel AL. Cellular interaction between B and T lymphocytes: enhanced release of B cell growth factor. *Lymphokine Res* 1986;5:49-57
24. **Sandler RS**, Golden AL. Epidemiology of Crohn's Disease. *J Clin Gastroenterol* 1986;8:160-5
25. **Sandler RS**, Maule WF, Baltus ME. Factors associated with postoperative complications in diabetics after biliary tract surgery. *Gastroenterology* 1986;91:157-62
26. Blalock SJ, DeVellis BM, **Sandler RS**. Participation in fecal occult blood screening: a critical review. *Prev Med* 1987;16:9-18
27. Kittinger JW, **Sandler RS**, Heizer WD. Efficacy of metoclopramide as an adjunct to duodenal placement of small-bore feeding tubes: a randomized, placebo-controlled, double-blind study. *JPEN J Parenter Enteral Nutr* 1987;11:33-7
28. Provenzale D, **Sandler RS**, Wood DR, Levinson SL, Frakes JT, Sartor RB, Jackson AL, Kinard HB, Wagner EH, Powell DW. Development of a scoring system to predict mortality from upper gastrointestinal bleeding. *Am J Med Sci* 1987;294:26-32

29. **Sandler RS.** Breast cancer awareness. *N C Med J* 1987;48:499-500
30. **Sandler RS,** Drossman DA. Bowel habits in young adults not seeking health care. *Dig Dis Sci* 1987;32:841-5
31. **Sandler RS,** Holland KL. Trends in gastric cancer sex ratio in the United States. *Cancer* 1987;59:1032-5
32. **Sandler RS,** Maule WF, Baltus ME, Holland KL, Kendall MS. Biliary tract surgery in the elderly. *J Gen Intern Med* 1987;2:149-54
33. Drossman DA, McKee DC, **Sandler RS,** Mitchell CM, Cramer EM, Lowman BC, Burger AL. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. *Gastroenterology* 1988;95:701-8
34. Provenzale D, Martin ZZ, Holland KL, **Sandler RS.** Colon adenomas in patients with hyperplastic polyps. *J Clin Gastroenterol* 1988;10:46-9
35. **Sandler RS,** Jordan MC, Kupper LL. Development of a Crohn's index for survey research. *J Clin Epidemiol* 1988;41:451-8
36. **Sandler RS,** Martin ZZ, Carlton NM, Holland KL. Adenomas of the large bowel after cholecystectomy. A case-control study. *Dig Dis Sci* 1988;33:1178-84
37. **Sandler RS,** Sandler DP, Comstock GW, Helsing KJ, Shore DL. Cigarette smoking and the risk of colorectal cancer in women. *J Natl Cancer Inst* 1988;80:1329-33
38. Narendranathan M, **Sandler RS,** Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. *J Clin Gastroenterol* 1989;11:403-6
39. **Sandler RS,** DeVellis BM, Blalock SJ, Holland KL. Participation of high-risk subjects in colon cancer screening. *Cancer* 1989;63:2211-5
40. **Sandler RS,** Holland KL, Brooks E, Konrad TR, Guild PA. Physicians' opinions and use of colorectal cancer screening procedures. *N C Med J* 1989;50:452-5
41. Baird DD, Narendranathan M, **Sandler RS.** Increased risk of preterm birth for women with inflammatory bowel disease. *Gastroenterology* 1990;99:987-94
42. Blalock SJ, DeVellis BM, Afifi RA, **Sandler RS.** Risk perceptions and participation in colorectal cancer screening. *Health Psychol* 1990;9:792-806
43. Provenzale D, Garrett JW, Condon SE, **Sandler RS.** Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps. *Ann Intern Med* 1990;113:760-3
44. **Sandler RS.** Epidemiology of irritable bowel syndrome in the United States. *Gastroenterology* 1990;99:409-15
45. **Sandler RS,** Holland KL. Fate of incorrectly addressed mailed questionnaires. *J Clin Epidemiol* 1990;43:45-7
46. **Sandler RS,** Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. *Am J Public Health* 1990;80:185-9 1404600.
47. Haynes RB, **Sandler RS,** Larson EB, Pater JL, Yatsu FM. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. *Arch Intern Med* 1992;152:1376-80
48. Sahai A, **Sandler RS,** Xu G, Shayman JA, Tannen RL. Signal transduction events whereby PGF2 alpha inhibits the ammoniagenic response to acute acidosis. *Am J Physiol* 1992;262:F950-6
49. Sahai A, Xu G, **Sandler RS,** Tannen RL. Hypoxia-mediated impaired differentiation by LLC-PK1 cells: evidence based on the protein kinase C profile. *Kidney Int* 1992;42:1145-52
50. **Sandler RS,** Sandler DP, McDonnell CW, Wurzelmann JI. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis. *Am J Epidemiol* 1992;135:603-8
51. **Sandler RS,** Ulshen MH, Lyles CM, McAuliffe CA, Fuller CR. Rectal mucosal ornithine decarboxylase activity is not a useful marker of risk for colorectal neoplasia. *Dig Dis Sci* 1992;37:1718-24
52. **Sandler RS,** Wurzelmann JI, Lyles CM. Oral contraceptive use and the risk of inflammatory bowel disease. *Epidemiology* 1992;3:374-8
53. **Sandler RS.** Cholecystectomy and colorectal cancer. *Gastroenterology* 1993;105:286-8
54. **Sandler RS,** Lyles CM, McAuliffe C, Woosley JT, Kupper LL. Cigarette smoking, alcohol, and the risk of colorectal adenomas. *Gastroenterology* 1993;104:1445-51
55. **Sandler RS,** Lyles CM, Peipins LA, McAuliffe CA, Woosley JT, Kupper LL. Diet and risk of colorectal adenomas: macronutrients, cholesterol, and fiber. *J Natl Cancer Inst* 1993;85:884-91
56. Campbell MK, DeVellis BM, Strecher VJ, Ammerman AS, DeVellis RF, **Sandler RS.** Improving dietary behavior: the effectiveness of tailored messages in primary care settings. *Am J Public Health* 1994;84:783-7 1615043.

57. Eisen GM, **Sandler RS**. Are women with breast cancer more likely to develop colorectal cancer? Critical review and meta-analysis. *J Clin Gastroenterol* 1994;19:57-63
58. Levine AA, **Sandler RS**. Screening for human immunodeficiency virus in physicians. Who should we test and what will it cost. *N C Med J* 1994;55:136-40
59. Lyles CM, **Sandler RS**, Keku TO, Kupper LL, Millikan RC, Murray SC, Bangdiwala SI, Ulshen MH. Reproducibility and variability of the rectal mucosal proliferation index using proliferating cell nuclear antigen immunohistochemistry. *Cancer Epidemiol Biomarkers Prev* 1994;3:597-605
60. Nissim I, Sahai A, **Sandler RS**, Tannen RL. The intensity of acidosis differentially alters the pathways of ammoniogenesis in LLC-PK1 cells. *Kidney Int* 1994;45:1014-9
61. Peipins LA, **Sandler RS**. Epidemiology of colorectal adenomas. *Epidemiol Rev* 1994;16:273-97
62. Sahai A, Fadda GZ, **Sandler RS**, Tannen RL. PGF2 alpha activation of Na/H antiporter and ammoniogenesis in parent/variant LLC-PK1 cells. *Kidney Int* 1994;46:1069-73
63. **Sandler RS**. Who wants a healthful breakfast? *N Engl J Med* 1994;330:1162
64. Wurzelmann JI, Lyles CM, **Sandler RS**. Childhood infections and the risk of inflammatory bowel disease. *Dig Dis Sci* 1994;39:555-60
65. Eisen GM, **Sandler RS**, Wurzelmann JI, Ransohoff DF, Talal A. Evaluating risk: a primer for gastroenterologists. *Am J Gastroenterol* 1995;90:704-7
66. Gomez GG, **Sandler RS**, Seal E, Jr. High levels of inorganic sulfate cause diarrhea in neonatal piglets. *J Nutr* 1995;125:2325-32
67. Murray SC, **Sandler RS**, Keku TO, Lyles CM, Millikan RC, Bangdiwala SI, Kupper LL, Jiang W, Ulshen MH. Comparison of rectal mucosal proliferation measured by proliferating cell nuclear antigen (PCNA) immunohistochemistry and whole crypt dissection. *Cancer Epidemiol Biomarkers Prev* 1995;4:715-20
68. Sahai A, Nissim I, **Sandler RS**, Tannen RL. Prostaglandin F2 alpha- and 12-O-tetradecanoylphorbol-13-acetate-induced alterations in the pathways of renal ammoniogenesis. *J Am Soc Nephrol* 1995;5:1792-8
69. **Sandler RS**, Eisen GM, Talal A, Wurzelmann JI. Rational approach to small polyps found on sigmoidoscopy. *J Clin Gastroenterol* 1995;20:317-20
70. **Sandler RS**, Nyren O, Ekblom A, Eisen GM, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia. A population-based study. *JAMA* 1995;274:1359-62
71. **Sandler RS**, Pritchard ML, Bangdiwala SI. Physical activity and the risk of colorectal adenomas. *Epidemiology* 1995;6:602-6
72. Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL, **Sandler RS**. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. *Cancer Epidemiol Biomarkers Prev* 1996;5:889-95
73. Godley PA, Campbell MK, Miller C, Gallagher P, Martinson FE, Mohler JL, **Sandler RS**. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. *Cancer Epidemiol Biomarkers Prev* 1996;5:115-9
74. **Sandler RS**. Epidemiology and risk factors for colorectal cancer. *Gastroenterol Clin North Am* 1996;25:717-35
75. **Sandler RS**. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. *Important Adv Oncol* 1996:123-37
76. Tseng M, Murray SC, Kupper LL, **Sandler RS**. Micronutrients and the risk of colorectal adenomas. *Am J Epidemiol* 1996;144:1005-14
77. Wurzelmann JI, Silver A, Schreinemachers DM, **Sandler RS**, Everson RB. Iron intake and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 1996;5:503-7
78. Baron JA, Greenberg ER, Haile R, Mandel J, **Sandler RS**, Mott L. Coffee and tea and the risk of recurrent colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1997;6:7-10
79. Eisen GM, **Sandler RS**, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. *Am J Gastroenterol* 1997;92:27-31
80. Freston JW, Ahnen DJ, Czinn SJ, Earnest DL, Farthing MJ, Gorbach SL, Hunt RH, **Sandler RS**, Schuster MM. Review and analysis of the effects of olestra, a dietary fat substitute, on gastrointestinal function and symptoms. *Regul Toxicol Pharmacol* 1997;26:210-8
81. Heizer WD, **Sandler RS**, Seal E, Jr., Murray SC, Busby MG, Schliebe BG, Pusek SN. Intestinal effects of sulfate in drinking water on normal human subjects. *Dig Dis Sci* 1997;42:1055-61
82. Licato LL, Keku TO, Wurzelmann JI, Murray SC, Woosley JT, **Sandler RS**, Brenner DA. In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. *Gastroenterology* 1997;113:1589-98

83. Longnecker MP, Sandler DP, Haile RW, **Sandler RS**. Phenolphthalein-containing laxative use in relation to adenomatous colorectal polyps in three studies. *Environ Health Perspect* 1997;105:1210-2 1470333.
84. Peipins LA, Newman B, **Sandler RS**. Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1997;6:671-5
85. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, **Sandler RS**. Plasma selenium levels and the risk of colorectal adenomas. *Nutr Cancer* 1997;28:125-9
86. Tseng M, **Sandler RS**, Greenberg ER, Mandel JS, Haile RW, Baron JA. Dietary iron and recurrence of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1997;6:1029-32
87. Baron JA, **Sandler RS**, Haile RW, Mandel JS, Mott LA, Greenberg ER. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. *J Natl Cancer Inst* 1998;90:57-62
88. Hyman J, Baron JA, Dain BJ, **Sandler RS**, Haile RW, Mandel JS, Mott LA, Greenberg ER. Dietary and supplemental calcium and the recurrence of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1998;7:291-5
89. Keku TO, Galanko JA, Murray SC, Woosley JT, **Sandler RS**. Rectal mucosal proliferation, dietary factors, and the risk of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1998;7:993-9
90. Russo MW, **Sandler RS**, Mandelkehr L, Fair JH, Johnson MW, Brown RS, Jr. Payer status, but not race, affects the cost of liver transplantation. *Liver Transpl Surg* 1998;4:370-7
91. **Sandler RS**. Appendectomy and ulcerative colitis. *Lancet* 1998;352:1797-8
92. **Sandler RS**. The incidence of IBD is higher in the North. *Inflamm Bowel Dis* 1998;4:175-6
93. **Sandler RS**, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. *Gastroenterology* 1998;114:441-7
94. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, **Sandler RS**, Rothstein R, Summers RW, Snover DC, Beck GJ, Bond JH, Greenberg ER. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. *N Engl J Med* 1999;340:101-7
95. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, **Sandler RS**, Rothstein R, Summers RW, Snover DC, Beck GJ, Frankl H, Pearson L, Bond JH, Greenberg ER. Calcium supplements and colorectal adenomas. Polyp Prevention Study Group. *Ann N Y Acad Sci* 1999;889:138-45
96. Bensen SP, Cole BF, Mott LA, Baron JA, **Sandler RS**, Haile R. Colorectal hyperplastic polyps and risk of recurrence of adenomas and hyperplastic polyps. Polyps Prevention Study. *Lancet* 1999;354:1873-4
97. Helm JF, **Sandler RS**. Colorectal cancer screening. *Med Clin North Am* 1999;83:1403-22, vi
98. **Sandler RS**. Prevention of Colorectal Cancer. *Curr Treat Options Gastroenterol* 1999;2:27-33
99. **Sandler RS**, Zorich NL, Filloon TG, Wiseman HB, Lietz DJ, Brock MH, Royer MG, Miday RK. Gastrointestinal symptoms in 3181 volunteers ingesting snack foods containing olestra or triglycerides. A 6-week randomized, placebo-controlled trial. *Ann Intern Med* 1999;130:253-61
100. Stewart WF, Liberman JN, **Sandler RS**, Woods MS, Stemhagen A, Chee E, Lipton RB, Farup CE. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. *Am J Gastroenterol* 1999;94:3530-40
101. Tseng M, Everhart JE, **Sandler RS**. Dietary intake and gallbladder disease: a review. *Public Health Nutr* 1999;2:161-72
102. Zacks SL, **Sandler RS**, Biddle AK, Mauro MA, Brown RS, Jr. Decision-analysis of transjugular intrahepatic portosystemic shunt versus distal splenorenal shunt for portal hypertension. *Hepatology* 1999;29:1399-405
103. Baron JA, **Sandler RS**. Nonsteroidal anti-inflammatory drugs and cancer prevention. *Annu Rev Med* 2000;51:511-23
104. Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, **Sandler RS**. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. *Am J Gastroenterol* 2000;95:3250-8
105. Kinney AY, Choi YA, DeVellis B, Kobetz E, Millikan RC, **Sandler RS**. Interest in genetic testing among first-degree relatives of colorectal cancer patients. *Am J Prev Med* 2000;18:249-52
106. Kinney AY, Choi YA, DeVellis B, Millikan R, Kobetz E, **Sandler RS**. Attitudes toward genetic testing in patients with colorectal cancer. *Cancer Pract* 2000;8:178-86
107. McKelvey W, Greenland S, **Sandler RS**. A second look at the relation between colorectal adenomas and consumption of foods containing partially hydrogenated oils. *Epidemiology* 2000;11:469-73
108. Ricci JA, Siddique R, Stewart WF, **Sandler RS**, Sloan S, Farup CE. Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes. *Scand J Gastroenterol* 2000;35:152-9

109. Russo MW, Zacks SL, **Sandler RS**, Brown RS. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. *Hepatology* 2000;31:358-63
110. **Sandler RS**, Baron JA, Tosteson TD, Mandel JS, Haile RW. Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial. *Cancer Epidemiol Biomarkers Prev* 2000;9:653-6
111. **Sandler RS**, Cummings MS, Keku TO, Terse A, Mehta N. Disposable versus reusable biopsy forceps for colorectal epithelial cell proliferation in humans. *Cancer Epidemiol Biomarkers Prev* 2000;9:1123-5
112. **Sandler RS**, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. *Dig Dis Sci* 2000;45:1166-71
113. Shaheen NJ, Crosby MA, Bozyski EM, **Sandler RS**. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? *Gastroenterology* 2000;119:333-8
114. Shaheen NJ, Crosby MA, O'Malley MS, Murray SC, **Sandler RS**, Galanko JA, Ransohoff DF, Klenzak JS. The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening. *Am J Gastroenterol* 2000;95:3259-65
115. Straus WL, Eisen GM, **Sandler RS**, Murray SC, Sessions JT. Crohn's disease: does race matter? The Mid-Atlantic Crohn's Disease Study Group. *Am J Gastroenterol* 2000;95:479-83
116. Tseng M, DeVellis RF, Maurer KR, Khare M, Kohlmeier L, Everhart JE, **Sandler RS**. Food intake patterns and gallbladder disease in Mexican Americans. *Public Health Nutr* 2000;3:233-43
117. Tseng M, Greenberg ER, **Sandler RS**, Baron JA, Haile RW, Blumberg BS, McGlynn KA. Serum ferritin concentration and recurrence of colorectal adenoma. *Cancer Epidemiol Biomarkers Prev* 2000;9:625-30
118. Tseng M, Millikan R, Maurer KR, Khare M, Everhart JE, **Sandler RS**. Country of birth and prevalence of gallbladder disease in Mexican Americans. *Ethn Dis* 2000;10:96-105
119. Beavers KL, **Sandler RS**, Fair JH, Johnson MW, Shrestha R. The living donor experience: donor health assessment and outcomes after living donor liver transplantation. *Liver Transpl* 2001;7:943-7
120. O'Malley MS, Shaheen NJ, Crosby MA, Murray SC, Klenzak JS, Galanko JA, Singla A, Ransohoff DF, **Sandler RS**, Gaither J, Paskett ED. Colorectal cancer screening in North Carolina. Community clinicians' perspectives. *N C Med J* 2001;62:292-7
121. Robertson DJ, **Sandler RS**. Measles virus and Crohn's disease: a critical appraisal of the current literature. *Inflamm Bowel Dis* 2001;7:51-7
122. **Sandler RS**. Reporting randomized controlled trials in gastroenterology: the CONSORT statement. *Gastroenterology* 2001;121:755
123. **Sandler RS**. American Gastroenterological Association. Presentation of the Julius M. Friedenwald Medal to Don W. Powell, M.D. *Gastroenterology* 2001;120:1854-9
124. **Sandler RS**, Halabi S, Kaplan EB, Baron JA, Paskett E, Petrelli NJ. Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. *Cancer* 2001;91:1040-5
125. Beavers KL, **Sandler RS**, Shrestha R. Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. *Liver Transpl* 2002;8:110-7
126. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, Zhou H, Gim JS, Ma HL, Matthies CF, Dai A, Huang HF, Materi AM, Lin JH, Frankl HD, Lee ER, Hardy SI, Herschman HR, Henderson BE, Kolonel LN, Le Marchand L, Garavito RM, **Sandler RS**, Haile RW, Smith WL. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. *Cancer Epidemiol Biomarkers Prev* 2002;11:1305-15
127. Martin C, Connelly A, Keku TO, Mountcastle SB, Galanko J, Woosley JT, Schliebe B, Lund PK, **Sandler RS**. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. *Gastroenterology* 2002;123:1770-7
128. Ransohoff DF, **Sandler RS**. Clinical practice. Screening for colorectal cancer. *N Engl J Med* 2002;346:40-4
129. Robertson DJ, Lawrence LB, Shaheen NJ, Baron JA, Paskett E, Petrelli NJ, **Sandler RS**. Quality of colonoscopy reporting: a process of care study. *Am J Gastroenterol* 2002;97:2651-6
130. **Sandler RS**. Writing clinical research grant applications. *Inflamm Bowel Dis* 2002;8:196-200
131. **Sandler RS**, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. *Gastroenterology* 2002;122:1500-11
132. Shaheen NJ, Provenzale D, **Sandler RS**. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. *Am J Gastroenterol* 2002;97:1319-27
133. Shaheen NJ, Straus WL, **Sandler RS**. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. *Cancer* 2002;94:950-63

134. Shih YC, Barghout VE, **Sandler RS**, Jhingran P, Sasane M, Cook S, Gibbons DC, Halpern M. Resource utilization associated with irritable bowel syndrome in the United States 1987-1997. *Dig Dis Sci* 2002;47:1705-15
135. Terry MB, Neugut AI, Bostick RM, **Sandler RS**, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD. Risk factors for advanced colorectal adenomas: a pooled analysis. *Cancer Epidemiol Biomarkers Prev* 2002;11:622-9
136. Zacks SL, **Sandler RS**, Rutledge R, Brown RS, Jr. A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. *Am J Gastroenterol* 2002;97:334-40
137. Baron JA, Cole BF, **Sandler RS**, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003;348:891-9
138. Butler LM, Sinha R, Millikan RC, Martin CF, Newman B, Gammon MD, Ammerman AS, **Sandler RS**. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. *Am J Epidemiol* 2003;157:434-45
139. Connelly AE, Satia-Abouta J, Martin CF, Keku TO, Woosley JT, Lund PK, **Sandler RS**. Vitamin C intake and apoptosis in normal rectal epithelium. *Cancer Epidemiol Biomarkers Prev* 2003;12:559-65
140. Grau MV, Baron JA, **Sandler RS**, Haile RW, Beach ML, Church TR, Heber D. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. *J Natl Cancer Inst* 2003;95:1765-71
141. Il'yasova D, Hodgson ME, Martin C, Galanko J, **Sandler RS**. Tea consumption, apoptosis, and colorectal adenomas. *Eur J Cancer Prev* 2003;12:439-43
142. Il'yasova D, Martin C, **Sandler RS**. Tea intake and risk of colon cancer in African-Americans and whites: North Carolina colon cancer study. *Cancer Causes Control* 2003;14:767-72
143. Keku TO, Millikan RC, Martin C, Rahrkra-Burris TK, **Sandler RS**. Family history of colon cancer: what does it mean and how is it useful? *Am J Prev Med* 2003;24:170-6
144. Kinney AY, Bloor LE, Dudley WN, Millikan RC, Marshall E, Martin C, **Sandler RS**. Roles of religious involvement and social support in the risk of colon cancer among Blacks and Whites. *Am J Epidemiol* 2003;158:1097-107
145. Rabeneck L, El-Serag HB, Davila JA, **Sandler RS**. Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). *Am J Gastroenterol* 2003;98:471-7
146. Roberts MC, Millikan RC, Galanko JA, Martin C, **Sandler RS**. Constipation, laxative use, and colon cancer in a North Carolina population. *Am J Gastroenterol* 2003;98:857-64
147. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, **Sandler RS**. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. *Gastroenterology* 2003;125:380-8
148. **Sandler RS**, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med* 2003;348:883-90
149. Satia-Abouta J, Galanko JA, Martin CF, Potter JD, Ammerman A, **Sandler RS**. Associations of micronutrients with colon cancer risk in African Americans and whites: results from the North Carolina Colon Cancer Study. *Cancer Epidemiol Biomarkers Prev* 2003;12:747-54
150. Satia-Abouta J, Galanko JA, Potter JD, Ammerman A, Martin CF, **Sandler RS**, North Carolina Colon Cancer S. Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. *Am J Epidemiol* 2003;158:951-62
151. Shaheen NJ, Lawrence LB, Bacon BR, Barton JC, Barton NH, Galanko J, Martin CF, Burnett CK, **Sandler RS**. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. *Am J Gastroenterol* 2003;98:1175-80
152. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlf EM, Martin CF, Galanko J, **Sandler RS**. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. *J Natl Cancer Inst* 2003;95:154-9
153. Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP, Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, Provenzale DT, **Sandler RS**, van Ryn M, Wallace RB, Weeks JC, West DW. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. *J Clin Oncol* 2004;22:2992-6
154. Fisher DA, Dougherty K, Martin C, Galanko J, Provenzale D, **Sandler RS**. Race and colorectal cancer screening: a population-based study in North Carolina. *N C Med J* 2004;65:12-5

155. Fisher DA, Martin C, Galanko J, **Sandler RS**, Noble MD, Provenzale D. Risk factors for advanced disease in colorectal cancer. *Am J Gastroenterol* 2004;99:2019-24
156. Jung B, Doctolero RT, Tajima A, Nguyen AK, Keku T, **Sandler RS**, Carethers JM. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. *Gastroenterology* 2004;126:654-9
157. Miller EA, Woosley J, Martin CF, **Sandler RS**. Hospital-to-hospital variation in lymph node detection after colorectal resection. *Cancer* 2004;101:1065-71
158. Russo MW, Wei JT, Thiny MT, Gangarosa LM, Brown A, Ringel Y, Shaheen NJ, **Sandler RS**. Digestive and liver diseases statistics, 2004. *Gastroenterology* 2004;126:1448-53
159. **Sandler RS**. Colonoscopy: virtual, optical, or chromoscopic? *Gastroenterology* 2004;126:641
160. **Sandler RS**. Aspirin prevention of colorectal cancer: more or less? *Ann Intern Med* 2004;140:224-5
161. Satia JA, Campbell MK, Galanko JA, James A, Carr C, **Sandler RS**. Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. *Cancer Epidemiol Biomarkers Prev* 2004;13:1022-31
162. Satia-Abouta J, Galanko JA, Martin CF, Ammerman A, **Sandler RS**. Food groups and colon cancer risk in African-Americans and Caucasians. *Int J Cancer* 2004;109:728-36
163. Sultan S, Fisher DA, Voils CI, Kinney AY, **Sandler RS**, Provenzale D. Impact of functional support on health-related quality of life in patients with colorectal cancer. *Cancer* 2004;101:2737-43
164. Wallace K, Baron JA, Cole BF, **Sandler RS**, Karagas MR, Beach MA, Haile RW, Burke CA, Pearson LH, Mandel JS, Rothstein R, Snover DC. Effect of calcium supplementation on the risk of large bowel polyps. *J Natl Cancer Inst* 2004;96:921-5
165. Wei JT, Connelly AE, Satia JA, Martin CF, **Sandler RS**. Eating frequency and colon cancer risk. *Nutr Cancer* 2004;50:16-22
166. Wei JT, Miller EA, Woosley JT, Martin CF, **Sandler RS**. Quality of colon carcinoma pathology reporting: a process of care study. *Cancer* 2004;100:1262-7
167. Williams RE, Hartmann KE, **Sandler RS**, Miller WC, Steege JF. Prevalence and characteristics of irritable bowel syndrome among women with chronic pelvic pain. *Obstet Gynecol* 2004;104:452-8
168. Baron JA, Beach M, Wallace K, Grau MV, **Sandler RS**, Mandel JS, Heber D, Greenberg ER. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. *Cancer Epidemiol Biomarkers Prev* 2005;14:586-9
169. Beskow LM, **Sandler RS**, Millikan RC, Weinberger M. Patient perspectives on research recruitment through cancer registries. *Cancer Causes Control* 2005;16:1171-5
170. Bresalier RS, **Sandler RS**, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanos A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx Trial I. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;352:1092-102
171. Butler LM, Duguay Y, Millikan RC, Sinha R, Gagne JF, **Sandler RS**, Guillemette C. Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1626-32
172. Grau MV, Baron JA, Barry EL, **Sandler RS**, Haile RW, Mandel JS, Cole BF. Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 2005;14:2353-8
173. Guiler M, Connelly-Frost A, Keku TO, Martin CF, Galanko J, **Sandler RS**. Does physical activity modify the association between body mass index and colorectal adenomas? *Nutr Cancer* 2005;51:140-5
174. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, **Sandler RS**. Insulin resistance, apoptosis, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev* 2005;14:2076-81
175. Kinney AY, Bloor LE, Martin C, **Sandler RS**. Social ties and colorectal cancer screening among Blacks and Whites in North Carolina. *Cancer Epidemiol Biomarkers Prev* 2005;14:182-9
176. Miller EA, Keku TO, Satia JA, Martin CF, Galanko JA, **Sandler RS**. Calcium, vitamin D, and apoptosis in the rectal epithelium. *Cancer Epidemiol Biomarkers Prev* 2005;14:525-8
177. Robertson DJ, Burke CA, Schwender BJ, Wargovich MJ, Greenberg ER, **Sandler RS**, Ahnen DJ, Rothstein R, Mott LA, Baron JA. Histamine receptor antagonists and incident colorectal adenomas. *Aliment Pharmacol Ther* 2005;22:123-8
178. Robertson DJ, Greenberg ER, Beach M, **Sandler RS**, Ahnen D, Haile RW, Burke CA, Snover DC, Bresalier RS, McKeown-Eyssen G, Mandel JS, Bond JH, Van Stolk RU, Summers RW, Rothstein R, Church TR, Cole BF, Byers T, Mott L, Baron JA. Colorectal cancer in patients under close colonoscopic surveillance. *Gastroenterology* 2005;129:34-41
179. Robertson DJ, **Sandler RS**, Haile R, Tosteson TD, Greenberg ER, Grau M, Baron JA. Fat, fiber, meat and the risk of colorectal adenomas. *Am J Gastroenterol* 2005;100:2789-95

180. **Sandler RS.** Quality of care in gastroenterology: beyond the bell curve. *Gastroenterology* 2005;128:1158
181. **Sandler RS.** Calcium supplements to prevent colorectal adenomas. *Am J Gastroenterol* 2005;100:395-6
182. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, **Sandler RS.** Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. *Am J Epidemiol* 2005;162:548-58
183. Satia JA, Keku T, Galanko JA, Martin C, Doctolero RT, Tajima A, **Sandler RS,** Carethers JM. Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. *Cancer Epidemiol Biomarkers Prev* 2005;14:429-36
184. Wallace K, Baron JA, Karagas MR, Cole BF, Byers T, Beach MA, Pearson LH, Burke CA, Silverman WB, **Sandler RS.** The association of physical activity and body mass index with the risk of large bowel polyps. *Cancer Epidemiol Biomarkers Prev* 2005;14:2082-6
185. Wei JT, Mott LA, Baron JA, **Sandler RS,** Polyp Prevention Study G. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 2005;14:1026-7
186. Williams RE, Hartmann KE, **Sandler RS,** Miller WC, Savitz LA, Steege JF. Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain. *Am J Obstet Gynecol* 2005;192:761-7
187. Wolf DC, Katz S, Safdi MA, **Sandler RS,** Lewis JD. Site organization and management. *Inflamm Bowel Dis* 2005;11 Suppl 1:S29-33
188. American Gastroenterological A, Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, Hunt R, Ladabaum U, Lanas A, Paulus H, Regueiro C, **Sandler RS,** Simon L. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. *Clin Gastroenterol Hepatol* 2006;4:1082-9
189. Austin GL, Shaheen NJ, **Sandler RS.** Positive and negative predictive values: use of inflammatory bowel disease serologic markers. *Am J Gastroenterol* 2006;101:413-6
190. Baron JA, **Sandler RS,** Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, Investigators APT. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. *Gastroenterology* 2006;131:1674-82
191. Barry EL, Baron JA, Bhat S, Grau MV, Burke CA, **Sandler RS,** Ahnen DJ, Haile RW, O'Brien TG. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. *J Natl Cancer Inst* 2006;98:1494-500
192. Beskow LM, Millikan RC, **Sandler RS,** Godley PA, Weiner BJ, Weinberger M. The effect of physician permission versus notification on research recruitment through cancer registries (United States). *Cancer Causes Control* 2006;17:315-23
193. Beskow LM, **Sandler RS,** Weinberger M. Research recruitment through US central cancer registries: balancing privacy and scientific issues. *Am J Public Health* 2006;96:1920-6 1751818.
194. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, **Sandler RS.** Selenium, apoptosis, and colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 2006;15:486-93
195. Huang K, **Sandler RS,** Millikan RC, Schroeder JC, North KE, Hu J. GSTM1 and GSTT1 polymorphisms, cigarette smoking, and risk of colon cancer: a population-based case-control study in North Carolina (United States). *Cancer Causes Control* 2006;17:385-94
196. James AS, Campbell MK, DeVellis B, Reedy J, Carr C, **Sandler RS.** Health behavior correlates among colon cancer survivors: NC STRIDES baseline results. *Am J Health Behav* 2006;30:720-30
197. Jung B, Smith EJ, Doctolero RT, Gervaz P, Alonso JC, Miyai K, Keku T, **Sandler RS,** Carethers JM. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. *Int J Cancer* 2006;118:2509-13 4155491.
198. Kim S, Baron JA, Mott LA, Burke CA, Church TR, McKeown-Eyssen GE, Cole BF, Haile RW, **Sandler RS.** Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). *Cancer Causes Control* 2006;17:1299-304
199. Kinney AY, Harrell J, Slattery M, Martin C, **Sandler RS.** Rural-urban differences in colon cancer risk in blacks and whites: the North Carolina Colon Cancer Study. *J Rural Health* 2006;22:124-30
200. Morgan DR, Dominguez RL, Keku TO, Heidt PE, Martin CF, Galanko JA, Omofoye OA, **Sandler RS.** Gastric cancer and the high combination prevalence of host cytokine genotypes and *Helicobacter pylori* in Honduras. *Clin Gastroenterol Hepatol* 2006;4:1103-11
201. **Sandler RS.** Cybermedicine and the gastroenterologist. *Gastroenterology* 2006;130:1028

202. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, de Cotret AR, Player J, **Sandler RS**. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). *Cancer Causes Control* 2006;17:257-66
203. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, Russo MW, **Sandler RS**. The burden of gastrointestinal and liver diseases, 2006. *Am J Gastroenterol* 2006;101:2128-38
204. Wei JT, **Sandler RS**. The right test for colon cancer screening? *Gastrointest Endosc* 2006;63:459-60
205. Austin GL, Adair LS, Galanko JA, Martin CF, Satia JA, **Sandler RS**. A diet high in fruits and low in meats reduces the risk of colorectal adenomas. *J Nutr* 2007;137:999-1004
206. Austin GL, Herfarth HH, **Sandler RS**. A critical evaluation of serologic markers for inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007;5:545-7
207. Cole BF, Baron JA, **Sandler RS**, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER, Polyp Prevention Study G. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. *JAMA* 2007;297:2351-9
208. Dellon ES, Aderoju A, Woosley JT, **Sandler RS**, Shaheen NJ. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. *Am J Gastroenterol* 2007;102:2300-13
209. Dorn SD, **Sandler RS**. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. *Am J Gastroenterol* 2007;102:662-7
210. Grau MV, Baron JA, **Sandler RS**, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, Snover DC, Rothstein R, Mandel JS. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. *J Natl Cancer Inst* 2007;99:129-36
211. Hansen RA, Gartlehner G, Powell GE, **Sandler RS**. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. *Clin Gastroenterol Hepatol* 2007;5:729-35
212. Isaacs KL, **Sandler RS**, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ, Crohn's, Colitis Foundation of America Clinical A. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. *Inflamm Bowel Dis* 2007;13:1250-5
213. Jonas DE, Russell LB, **Sandler RS**, Chou J, Pignone M. Patient time requirements for screening colonoscopy. *Am J Gastroenterol* 2007;102:2401-10
214. Lanas A, Baron JA, **Sandler RS**, Horgan K, Bolognese J, Oxenius B, Quan H, Watson D, Cook TJ, Schoen R, Burke C, Loftus S, Niv Y, Ridell R, Morton D, Bresalier R. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. *Gastroenterology* 2007;132:490-7
215. Miller EA, Keku TO, Satia JA, Martin CF, Galanko JA, **Sandler RS**. Calcium, dietary, and lifestyle factors in the prevention of colorectal adenomas. *Cancer* 2007;109:510-7
216. Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, **Sandler RS**, Sharpless NE. RNA expression analysis of formalin-fixed paraffin-embedded tumors. *Lab Invest* 2007;87:383-91
217. **Sandler RS**. Best hospitals? *Gastroenterology* 2007;133:1064-7
218. Vinikoor LC, Robertson DJ, Baron JA, Silverman WB, **Sandler RS**. Cholecystectomy and the risk of recurrent colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 2007;16:1523-5
219. Austin GL, Galanko JA, Martin CF, **Sandler RS**. Moderate alcohol consumption protects against colorectal adenomas in smokers. *Dig Dis Sci* 2008;53:116-22 2664311.
220. Baron JA, **Sandler RS**, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. *Lancet* 2008;372:1756-64
221. Butler LM, Millikan RC, Sinha R, Keku TO, Winkel S, Harlan B, Eaton A, Gammon MD, **Sandler RS**. Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. *Mutat Res* 2008;638:162-74 2234436.
222. Corbie-Smith G, Blumenthal C, Henderson G, Garrett J, Bussey-Jones J, Moloney M, **Sandler RS**, Lloyd SW, Dorrance J, Darter J. Studying genetic research participants: lessons from the "Learning About Research in North Carolina" study. *Cancer Epidemiol Biomarkers Prev* 2008;17:2019-24 3037258.
223. Dellon ES, Lippmann QK, **Sandler RS**, Shaheen NJ. Gastrointestinal endoscopy nurse experience and polyp detection during screening colonoscopy. *Clin Gastroenterol Hepatol* 2008;6:1342-7 2615185.
224. Figueiredo JC, Levine AJ, Grau MV, Barry EL, Ueland PM, Ahnen DJ, Byers T, Bresalier RS, Summers RW, Bond J, McKeown-Eyssen GE, **Sandler RS**, Haile RW, Baron JA. Colorectal adenomas in a

- randomized folate trial: the role of baseline dietary and circulating folate levels. *Cancer Epidemiol Biomarkers Prev* 2008;17:2625-31 2597215.
225. Figueiredo JC, Levine AJ, Grau MV, Midttun O, Ueland PM, Ahnen DJ, Barry EL, Tsang S, Munroe D, Ali I, Haile RW, **Sandler RS**, Baron JA. Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. *Cancer Epidemiol Biomarkers Prev* 2008;17:2136-45 2518404.
 226. Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, **Sandler RS**, Guillemette C. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. *Mutat Res* 2008;644:56-63 2570038.
 227. Jonas DE, Russell LB, **Sandler RS**, Chou J, Pignone M. Value of patient time invested in the colonoscopy screening process: time requirements for colonoscopy study. *Med Decis Making* 2008;28:56-65
 228. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, **Sandler RS**, Galanko JA, Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008;135:1907-13 2613430.
 229. Keku TO, Amin A, Galanko J, Martin C, Schliebe B, **Sandler RS**. Apoptosis in normal rectal mucosa, baseline adenoma characteristics, and risk of future adenomas. *Cancer Epidemiol Biomarkers Prev* 2008;17:306-10 2636570.
 230. Keku TO, **Sandler RS**, Simmons JG, Galanko J, Woosley JT, Proffitt M, Omofoye O, McDoom M, Lund PK. Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomas. *BMC Cancer* 2008;8:143 2409350.
 231. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, **Sandler RS**. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. *Cancer Res* 2008;68:323-8 2675825.
 232. Kim S, Martin C, Galanko J, Woosley JT, Schroeder JC, Keku TO, Satia JA, Halabi S, **Sandler RS**. Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. *Am J Epidemiol* 2008;168:1292-300 2727267.
 233. Qu P, Chu H, Ibrahim JG, Peacock J, Shen XJ, Tepper J, **Sandler RS**, Keku TO. Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis. *Br J Cancer* 2008;99:2001-5 2607226.
 234. Ransohoff DF, Martin C, Wiggins WS, Hitt BA, Keku TO, Galanko JA, **Sandler RS**. Assessment of serum proteomics to detect large colon adenomas. *Cancer Epidemiol Biomarkers Prev* 2008;17:2188-93 2561171.
 235. Salz T, **Sandler RS**. The effect of hospital and surgeon volume on outcomes for rectal cancer surgery. *Clin Gastroenterol Hepatol* 2008;6:1185-93 2582059.
 236. **Sandler RS**. Realistic expectations after negative colonoscopy. *Clin Gastroenterol Hepatol* 2008;6:1068-9
 237. **Sandler RS**. Point/Counterpoint: Aspirin should not be promoted for colon cancer prevention: counterpoint. *Cancer Epidemiol Biomarkers Prev* 2008;17:1562-3
 238. Steck SE, Keku T, Butler LM, Galanko J, Massa B, Millikan RC, **Sandler RS**. Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk. *J Nutrigenet Nutrigenomics* 2008;1:196-204 2758622.
 239. Vinikoor LC, Galanko JA, **Sandler RS**. Cholecystectomy and the risk of colorectal adenomas. *Dig Dis Sci* 2008;53:730-5 2647516.
 240. Vinikoor LC, Schroeder JC, Millikan RC, Satia JA, Martin CF, Ibrahim J, Galanko JA, **Sandler RS**. Consumption of trans-fatty acid and its association with colorectal adenomas. *Am J Epidemiol* 2008;168:289-97 2533637.
 241. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, **Sandler RS**, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. *Cancer Epidemiol Biomarkers Prev* 2009;18:2726-33 2769932.
 242. Cole BF, Logan RF, Halabi S, Benamouzig R, **Sandler RS**, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. *J Natl Cancer Inst* 2009;101:256-66
 243. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, **Sandler RS**. Selenium, folate, and colon cancer. *Nutr Cancer* 2009;61:165-78 2743456.
 244. Crockett SD, Gulati A, **Sandler RS**, Kappelman MD. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. *Am J Gastroenterol* 2009;104:2387-93 2775814.

245. Dellon ES, Lippmann QK, Galanko JA, **Sandler RS**, Shaheen NJ. Effect of GI endoscopy nurse experience on screening colonoscopy outcomes. *Gastrointest Endosc* 2009;70:331-43 2753217.
246. Dorn SD, Farley JF, Hansen RA, Shah ND, **Sandler RS**. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions. *Gastroenterology* 2009;137:518-24, 524 e1-2 2717184.
247. Figueiredo JC, Grau MV, Haile RW, **Sandler RS**, Summers RW, Bresalier RS, Burke CA, McKeown-Eyssen GE, Baron JA. Folic acid and risk of prostate cancer: results from a randomized clinical trial. *J Natl Cancer Inst* 2009;101:432-5 2657096.
248. Grau MV, **Sandler RS**, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. *J Natl Cancer Inst* 2009;101:267-76 2644329.
249. Ho GY, Xue X, Cushman M, McKeown-Eyssen G, **Sandler RS**, Ahnen DJ, Barry EL, Saibil F, Bresalier RS, Rohan TE, Baron JA. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. *J Natl Cancer Inst* 2009;101:1650-4 2786916.
250. Joshi AD, Corral R, Siegmund KD, Haile RW, Le Marchand L, Martinez ME, Ahnen DJ, **Sandler RS**, Lance P, Stern MC. Red meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways and colorectal cancer risk. *Carcinogenesis* 2009;30:472-9 2722151.
251. Long MD, Porter CQ, **Sandler RS**, Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2009;7:549-53 2838487.
252. Palmer L, Herfarth H, Porter CQ, Fordham LA, **Sandler RS**, Kappelman MD. Diagnostic ionizing radiation exposure in a population-based sample of children with inflammatory bowel diseases. *Am J Gastroenterol* 2009;104:2816-23 2788488.
253. Robertson DJ, Burke CA, Welch HG, Haile RW, **Sandler RS**, Greenberg ER, Ahnen DJ, Bresalier RS, Rothstein RI, Cole B, Mott LA, Baron JA. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. *Ann Intern Med* 2009;151:103-9 2779048.
254. Robertson DJ, **Sandler RS**, Ahnen DJ, Greenberg ER, Mott LA, Cole BF, Baron JA. Gastrin, *Helicobacter pylori*, and colorectal adenomas. *Clin Gastroenterol Hepatol* 2009;7:163-7.
255. Rogers SO, Jr., Ayanian JZ, Ko CY, Kahn KL, Zaslavsky AM, **Sandler RS**, Keating NL. Surgeons' volume of colorectal cancer procedures and collaborative decision-making about adjuvant therapies. *Ann Surg* 2009;250:895-900 3122081.
256. Salz T, Brewer NT, **Sandler RS**, Weiner BJ, Martin CF, Weinberger M. Association of health beliefs and colonoscopy use among survivors of colorectal cancer. *J Cancer Surviv* 2009;3:193-201 2809816.
257. **Sandler RS**. How will we address the crucial questions facing our field? *Gastroenterology* 2009;137:e14-8.
258. Satia JA, Tseng M, Galanko JA, Martin C, **Sandler RS**. Dietary patterns and colon cancer risk in Whites and African Americans in the North Carolina Colon Cancer Study. *Nutr Cancer* 2009;61:179-93.
259. Vinikoor LC, Long MD, Keku TO, Martin CF, Galanko JA, **Sandler RS**. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. *Cancer Epidemiol Biomarkers Prev* 2009;18:1239-42 2709952.
260. Vinikoor LC, Satia JA, Schroeder JC, Millikan RC, Martin CF, Ibrahim JG, **Sandler RS**. Associations between trans fatty acid consumption and colon cancer among Whites and African Americans in the North Carolina colon cancer study I. *Nutr Cancer* 2009;61:427-36 2853475.
261. Williams CD, Satia JA, Adair LS, Stevens J, Galanko J, Keku TO, **Sandler RS**. Dietary patterns, food groups, and rectal cancer risk in Whites and African-Americans. *Cancer Epidemiol Biomarkers Prev* 2009;18:1552-61 2774490.
262. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, **Sandler RS**, Kim HJ, Keku TO, Der CJ. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. *Mol Cancer Ther* 2009;8:834-43 2729756.
263. Brevik A, Joshi AD, Corral R, Onland-Moret NC, Siegmund KD, Le Marchand L, Baron JA, Martinez ME, Haile RW, Ahnen DJ, **Sandler RS**, Lance P, Stern MC. Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. *Cancer Epidemiol Biomarkers Prev* 2010;19:3167-73 3058341.
264. Crockett SD, Porter CQ, Martin CF, **Sandler RS**, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. *Am J Gastroenterol* 2010;105:1986-93 3073620.
265. Devaraj B, Lee A, Cabrera BL, Miyai K, Luo L, Ramamoorthy S, Keku T, **Sandler RS**, McGuire KL, Carethers JM. Relationship of EMAS and microsatellite instability among patients with rectal cancer. *J Gastrointest Surg* 2010;14:1521-8 2943582.

266. Fisher DA, Zullig LL, Grambow SC, Abbott DH, **Sandler RS**, Fletcher RH, El-Serag HB, Provenzale D. Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. *Dig Dis Sci* 2010;55:1434-41 2864330.
267. Hamilton KE, Lund PK, Galanko JA, **Sandler RS**, Keku TO. Suppressor of cytokine signaling 3 (SOCS3) is not an independent biomarker of colorectal adenoma risk. *BMC Res Notes* 2010;3:144 2883989.
268. Kim S, Sandler DP, Galanko J, Martin C, **Sandler RS**. Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. *Am J Epidemiol* 2010;171:969-79 2877478.
269. Kupfer SS, Anderson JR, Hooker S, Skol A, Kittles RA, Keku TO, **Sandler RS**, Ellis NA. Genetic heterogeneity in colorectal cancer associations between African and European americans. *Gastroenterology* 2010;139:1677-85, 1685 e1-8 3721963.
270. Long MD, Herfarth HH, Pipkin CA, Porter CQ, **Sandler RS**, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2010;8:268-74 2838486.
271. Long MD, Martin CF, Galanko JA, **Sandler RS**. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. *Am J Gastroenterol* 2010;105:1843-50 2916940.
272. Long MD, Thiny MT, **Sandler RS**, Gangarosa LM. Bone health in a tertiary-care gastroenterology and hepatology population. *Dig Dis Sci* 2010;55:2263-9 2894281.
273. Salz T, Weinberger M, Ayanian JZ, Brewer NT, Earle CC, Elston Lafata J, Fisher DA, Weiner BJ, **Sandler RS**. Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. *BMC Health Serv Res* 2010;10:256 2941495.
274. **Sandler RS**. Editorial: colonoscopy and colorectal cancer mortality: strong beliefs or strong facts? *Am J Gastroenterol* 2010;105:1633-5
275. **Sandler RS**. Dietary and lifestyle measures to lower colorectal cancer risk. *Clin Gastroenterol Hepatol* 2010;8:329-32
276. Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, Jovov B, Abdo Z, **Sandler RS**, Keku TO. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. *Gut Microbes* 2010;1:138-47 2927011.
277. Vinikoor LC, Millikan RC, Satia JA, Schroeder JC, Martin CF, Ibrahim JG, **Sandler RS**. trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II. *Cancer Causes Control* 2010;21:171-80 2809818.
278. Williams CD, Satia JA, Adair LS, Stevens J, Galanko J, Keku TO, **Sandler RS**. Associations of red meat, fat, and protein intake with distal colorectal cancer risk. *Nutr Cancer* 2010;62:701-9 3023148.
279. Williams CD, Satia JA, Adair LS, Stevens J, Galanko J, Keku TO, **Sandler RS**. Antioxidant and DNA methylation-related nutrients and risk of distal colorectal cancer. *Cancer Causes Control* 2010;21:1171-81 3024035.
280. Barry EL, Mott LA, **Sandler RS**, Ahnen DJ, Baron JA. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention. *Cancer Prev Res (Phila)* 2011;4:2072-82 3232321.
281. Crockett SD, Long MD, Dellon ES, Martin CF, Galanko JA, **Sandler RS**. Inverse relationship between moderate alcohol intake and rectal cancer: analysis of the North Carolina Colon Cancer Study. *Dis Colon Rectum* 2011;54:887-94 3111915.
282. Kappelman MD, Galanko JA, Porter CQ, **Sandler RS**. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. *Arch Dis Child* 2011;96:1042-6
283. Kappelman MD, Galanko JA, Porter CQ, **Sandler RS**. Risk of diagnosed fractures in children with inflammatory bowel diseases. *Inflamm Bowel Dis* 2011;17:1125-30 3012144.
284. Kappelman MD, Horvath-Puho E, **Sandler RS**, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sorensen HT. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. *Gut* 2011;60:937-43
285. Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, **Sandler RS**, Finkelstein JA. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. *Inflamm Bowel Dis* 2011;17:62-8 2962765.
286. Kupfer SS, Anderson JR, Ludvik AE, Hooker S, Skol A, Kittles RA, Keku TO, **Sandler RS**, Ruiz-Ponte C, Castellvi-Bel S, Castells A, Carracedo A, Ellis NA. Genetic associations in the vitamin D receptor and colorectal cancer in African Americans and Caucasians. *PLoS One* 2011;6:e26123 3203108.

287. Long MD, Martin C, **Sandler RS**, Herfarth HH, Shaheen NJ, Dellon ES. Reduced polyp detection as endoscopy shift progresses: experience with screening colonoscopy at a tertiary-care hospital. *J Clin Gastroenterol* 2011;45:253-8
288. Lund JL, Sturmer T, Porter CQ, **Sandler RS**, Kappelman MD. Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data. *Inflamm Bowel Dis* 2011;17:787-94 3098467.
289. Shaughnessy DT, Gangarosa LM, Schliebe B, Umbach DM, Xu Z, MacIntosh B, Knize MG, Matthews PP, Swank AE, **Sandler RS**, DeMarini DM, Taylor JA. Inhibition of fried meat-induced colorectal DNA damage and altered systemic genotoxicity in humans by crucifera, chlorophyllin, and yogurt. *PLoS One* 2011;6:e18707 3081825.
290. Shaukat A, Grau MV, Church TR, Baxter G, Barry EL, Summers R, **Sandler RS**, Baron JA. Serum salicylate levels and risk of recurrent colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 2011;20:679-82 3708487.
291. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexø BA, Tjønneland A, Overvad K, Rudnai P, Gsurau E, Koppova K, Hemminki K, Corredera C, Fuentelsaz V, Grasa P, Navarrete S, Fuertes F, Garcia-Prats MD, Sanambrosio E, Panadero A, De Juan A, Garcia A, Rivera F, Planelles D, Soriano V, Requena C, Aben KK, van Rossum MM, Cremers RG, van Oort IM, van Spronsen DJ, Schalken JA, Peters WH, Helfand BT, Donovan JL, Hamdy FC, Badescu D, Codreanu O, Jinga M, Csiki IE, Constantinescu V, Badea P, Mates IN, Dinu DE, Constantin A, Mates D, Kristjansdottir S, Agnarsson BA, Jonsson E, Barkardottir RB, Einarsson GV, Sigurdsson F, Møller PH, Stefansson T, Valdimarsson T, Johannsson OT, Sigurdsson H, Jonsson T, Jonasson JG, Tryggvadottir L, Rice T, Hansen HM, Xiao Y, Lachance DH, BP ON, Kosel ML, Decker PA, Thorleifsson G, Johannsdottir H, Helgadóttir HT, Sigurdsson A, Steinthorsdottir V, Lindblom A, Swedish Low-risk Colorectal Cancer Study G, **Sandler RS**, Keku TO, Banasik K, Jorgensen T, Witte DR, Hansen T, Pedersen O, Jinga V, Neal DE, Catalona WJ, Wrensch M, Wiencke J, Jenkins RB, Nagore E, Vogel U, Kiemeny LA, Kumar R, Mayordomo JJ, Olafsson JH, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nat Genet* 2011;43:1098-103 3263694.
292. Araujo-Perez F, McCoy AN, Okechukwu C, Carroll IM, Smith KM, Jeremiah K, **Sandler RS**, Asher GN, Keku TO. Differences in microbial signatures between rectal mucosal biopsies and rectal swabs. *Gut Microbes* 2012;3:530-5 3495790.
293. Crockett SD, Hansen RA, Sturmer T, Schectman R, Darter J, **Sandler RS**, Kappelman MD. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. *Inflamm Bowel Dis* 2012;18:1048-56 3213287.
294. Dorn SD, Wei D, Farley JF, Shah ND, Shaheen NJ, **Sandler RS**, Kappelman MD. Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured. *Clin Gastroenterol Hepatol* 2012;10:278-84
295. Hoskins JM, Ong PS, Keku TO, Galanko JA, Martin CF, Coleman CA, Wolfe M, **Sandler RS**, McLeod HL. Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. *PLoS One* 2012;7:e41954 3407042.
296. Hoyo C, Murphy SK, Schildkraut JM, Vidal AC, Skaar D, Millikan RC, Galanko J, **Sandler RS**, Jirtle R, Keku T. IGF2R genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites. *Dis Markers* 2012;32:133-41 3751395.
297. Keku TO, Vidal A, Oliver S, Hoyo C, Hall IJ, Omofeye O, McDoom M, Worley K, Galanko J, **Sandler RS**, Millikan R. Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites. *Cancer Causes Control* 2012;23:1127-38 4212518.
298. Long MD, Kappelman MD, Martin CF, Lewis JD, Mayer L, Kinneer PM, **Sandler RS**. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. *Inflamm Bowel Dis* 2012;18:2099-106
299. Long MD, Martin CF, Pipkin CA, Herfarth HH, **Sandler RS**, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. *Gastroenterology* 2012;143:390-399 e1 4065572.
300. Peery AF, Barrett PR, Park D, Rogers AJ, Galanko JA, Martin CF, **Sandler RS**. A high-fiber diet does not protect against asymptomatic diverticulosis. *Gastroenterology* 2012;142:266-72 e1 3724216.
301. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, **Sandler**

- RS**, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012;143:1179-87 e1-3 3480553.
302. Sanapareddy N, Legge RM, Jovov B, McCoy A, Burcal L, Araujo-Perez F, Randall TA, Galanko J, Benson A, **Sandler RS**, Rawls JF, Abdo Z, Fodor AA, Keku TO. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. *ISME J* 2012;6:1858-68 3446812.
 303. Tippin BL, Levine AJ, Materi AM, Song WL, Keku TO, Goodman JE, Sansbury LB, Das S, Dai A, Kwong AM, Lin AM, Lin JM, Park JM, Patterson RE, Chlebowski RT, Garavito RM, Inoue T, Cho W, Lawson JA, Kapoor S, Kolonel LN, Le Marchand L, Haile RW, **Sandler RS**, Lin HJ. Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. *Prostaglandins Other Lipid Mediat* 2012;97:22-8 3226866.
 304. Tuupanen S, Yan J, Turunen M, Gylfe AE, Kaasinen E, Li L, Eng C, Culver DA, Kalady MF, Pennison MJ, Pasche B, Manne U, de la Chapelle A, Hampel H, Henderson BE, Le Marchand L, Hautaniemi S, Askhtorab H, Smoot D, **Sandler RS**, Keku T, Kupfer SS, Ellis NA, Haiman CA, Taipale J, Aaltonen LA. Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. *Cancer Genet* 2012;205:25-33 3770308.
 305. Vidal AC, Lund PK, Hoyo C, Galanko J, Burcal L, Holston R, Massa B, Omofoye O, **Sandler RS**, Keku TO. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. *BMC Cancer* 2012;12:389 3489909.
 306. Wang J, Joshi AD, Corral R, Siegmund KD, Marchand LL, Martinez ME, Haile RW, Ahnen DJ, **Sandler RS**, Lance P, Stern MC. Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. *Int J Cancer* 2012;130:1898-907 3883510.
 307. Ananthakrishnan AN, Long MD, Martin CF, **Sandler RS**, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. *Clin Gastroenterol Hepatol* 2013;11:965-71 3659204.
 308. Barry EL, Poole EM, Baron JA, Makar KW, Mott LA, **Sandler RS**, Ahnen DJ, Bresalier RS, McKeown-Eyssen GE, Ulrich CM. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. *Cancer Causes Control* 2013;24:47-54 3529799.
 309. Berg BP, Murr M, Chermak D, Woodall J, Pignone M, **Sandler RS**, Denton BT. Estimating the cost of no-shows and evaluating the effects of mitigation strategies. *Med Decis Making* 2013;33:976-85 4153419.
 310. Cohen AB, Lee D, Long MD, Kappelman MD, Martin CF, **Sandler RS**, Lewis JD. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. *Dig Dis Sci* 2013;58:1322-8 3552110.
 311. Erichsen R, Baron JA, Stoffel EM, Laurberg S, **Sandler RS**, Sorensen HT. Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. *Am J Gastroenterol* 2013;108:1332-40.
 312. Erichsen R, Svaerke C, Sorensen HT, **Sandler RS**, Baron JA. Risk of colorectal cancer in patients with acute myocardial infarction and stroke: a nationwide cohort study. *Cancer Epidemiol Biomarkers Prev* 2013;22:1994-9.
 313. Frantz DJ, Crockett SD, Galanko JA, **Sandler RS**. Percent Body Fat Measured by Bioelectrical Impedance is Not Associated with Colorectal Adenoma Status. *J Gastroenterol Hepatol Res* 2013;2:445-448 3952152.
 314. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Jr., Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, **Sandler RS**, Sartor RB. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. *Inflamm Bowel Dis* 2013;19:1073-9.
 315. Hong JL, Meier CR, **Sandler RS**, Jick SS, Sturmer T. Risk of colorectal cancer after initiation of orlistat: matched cohort study. *BMJ* 2013;347:f5039 3754767.
 316. Kang M, Peery AF, Locklear C, Galanko JA, **Sandler RS**, Keku TO. Plasma insulin, glucose, IGF-I, IGF-II, and IGFBP-3 and risk of recurrent colorectal adenomas. *J Gastroenterol Hepatol Res* 2013;2:531-535 3922127.
 317. Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CF, **Sandler RS**, Keku TO. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. *Cancer Biomark* 2013;13:359-66.
 318. Long MD, Farraye FA, Okafor PN, Martin C, **Sandler RS**, Kappelman MD. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2013;19:1018-24 3879785.

319. Long MD, Martin C, **Sandler RS**, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. *Am J Gastroenterol* 2013;108:240-8
320. Long MD, Martin C, **Sandler RS**, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013;37:420-9 3886551.
321. Lund JL, Sturmer T, Harlan LC, Sanoff HK, **Sandler RS**, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. *Med Care* 2013;51:e27-34 3290707.
322. Lund JL, Sturmer T, Sanoff HK, Brookhart A, **Sandler RS**, Warren JL. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. *Cancer* 2013;119:2038-47 3663924.
323. Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, **Sandler RS**, Sturmer T. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. *Pharmacoepidemiol Drug Saf* 2013;22:810-8 3659185.
324. McCoy AN, Araujo-Perez F, Azcarate-Peril A, Yeh JJ, **Sandler RS**, Keku TO. Fusobacterium is associated with colorectal adenomas. *PLoS One* 2013;8:e53653 3546075.
325. Palmer LB, Kappelman MD, **Sandler RS**, Hayashi PH. Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population. *J Clin Gastroenterol* 2013;47:713-8 3745802.
326. Peery AF, **Sandler RS**. Diverticular disease: reconsidering conventional wisdom. *Clin Gastroenterol Hepatol* 2013;11:1532-7 3785555.
327. Peery AF, **Sandler RS**, Ahnen DJ, Galanko JA, Holm AN, Shaukat A, Mott LA, Barry EL, Fried DA, Baron JA. Constipation and a low-fiber diet are not associated with diverticulosis. *Clin Gastroenterol Hepatol* 2013;11:1622-7 3840096.
328. Randell RL, Long MD, Martin CF, **Sandler RS**, Chen W, Anton K, Kappelman MD. Patient perception of chronic illness care in a large inflammatory bowel disease cohort. *Inflamm Bowel Dis* 2013;19:1428-33
329. Rees JR, Hendricks K, Barry EL, Peacock JL, Mott LA, **Sandler RS**, Bresalier RS, Goodman M, Bostick RM, Baron JA. Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial. *Clin Infect Dis* 2013;57:1384-92 3805175.
330. Srygley FD, Abbott DH, Grambow SC, Provenzale D, **Sandler RS**, Fischer DA. Variability in resource use: diagnosing colorectal cancer. *Am J Manag Care* 2013;19:370-6
331. Wang H, Haiman CA, Burnett T, Fortini BK, Kolonel LN, Henderson BE, Signorello LB, Blot WJ, Keku TO, Berndt SI, Newcomb PA, Pande M, Amos CI, West DW, Casey G, **Sandler RS**, Haile R, Stram DO, Le Marchand L. Fine-mapping of genome-wide association study-identified risk loci for colorectal cancer in African Americans. *Hum Mol Genet* 2013;22:5048-55 3836473.
332. Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, **Sandler RS**. Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. *Clin Gastroenterol Hepatol* 2014
333. Barry EL, Mott LA, Melamed ML, Rees JR, Ivanova A, **Sandler RS**, Ahnen DJ, Bresalier RS, Summers RW, Bostick RM, Baron JA. Calcium supplementation increases blood creatinine concentration in a randomized controlled trial. *PLoS One* 2014;9:e108094 4198086.
334. Busch EL, McGraw KA, **Sandler RS**. The potential for markers of epithelial-mesenchymal transition to improve colorectal cancer outcomes: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2014;23:1164-75
335. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, Smith EJ, Lee M, Janke R, Ngo T, Tejada R, Ji M, Kinseth M, Cabrera BL, Miyai K, Keku TO, Martin CF, Galanko JA, **Sandler RS**, McGuire KL. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. *PLoS One* 2014;9:e100461 4067325.
336. Crockett SD, Mott LA, Barry EL, Figueiredo JC, Burke CA, Baxter GJ, **Sandler RS**, Baron JA. C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study. *Cancer Prev Res (Phila)* 2014;7:1122-7 4221539.
337. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, **Sandler RS**, Hanauer SB. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. *Aliment Pharmacol Ther* 2014;39:163-75 3918445.
338. Figueiredo JC, Crockett SD, Snover DC, Morris CB, McKeown-Eyssen G, **Sandler RS**, Ahnen DJ, Robertson DJ, Burke CA, Bresalier RS, Church JM, Church TR, Baron JA. Smoking-associated risks of conventional adenomas and serrated polyps in the colorectum. *Cancer Causes Control* 2014
339. Herfarth HH, Martin CF, **Sandler RS**, Kappelman MD, Long MD. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. *Inflamm Bowel Dis* 2014;20:1194-7

340. Kappelman MD, Farkas DK, Long MD, Erichsen R, **Sandler RS**, Sorensen HT, Baron JA. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. *Clin Gastroenterol Hepatol* 2014;12:265-73 e1
341. Kappelman MD, Long MD, Martin C, DeWalt DA, Kinneer PM, Chen W, Lewis JD, **Sandler RS**. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2014;12:1315-23 e2
342. Kupfer SS, Skol AD, Hong E, Ludvik A, Kittles RA, Keku TO, **Sandler RS**, Ellis NA. Shared and independent colorectal cancer risk alleles in TGFbeta-related genes in African and European Americans. *Carcinogenesis* 2014;35:2025-30 4146413.
343. Layton JB, Klemmer PJ, Christiansen CF, Bombback AS, Baron JA, **Sandler RS**, Kshirsagar AV. Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol. *Clin Gastroenterol Hepatol* 2014;12:1514-21 e3
344. Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV, Jr., Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, **Sandler RS**, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. *Inflamm Bowel Dis* 2014;20:398-415
345. Long MD, Kappelman MD, Martin CF, Chen W, Anton K, **Sandler RS**. Risk factors for depression in the elderly inflammatory bowel disease population. *J Crohns Colitis* 2014;8:113-9
346. Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, **Sandler RS**, Burke C, Hill DA, Ahnen DJ. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. *Cancer Epidemiol Biomarkers Prev* 2014;23:601-10 3976708.
347. Murphy CC, Lewis CL, Golin CE, **Sandler RS**. Underuse of Surveillance Colonoscopy in Patients at Increased Risk of Colorectal Cancer. *Am J Gastroenterol* 2014
348. Nugent JL, McCoy AN, Addamo CJ, Jia W, **Sandler RS**, Keku TO. Altered tissue metabolites correlate with microbial dysbiosis in colorectal adenomas. *J Proteome Res* 2014;13:1921-9 3993967.
349. Pibiri F, Kittles RA, **Sandler RS**, Keku TO, Kupfer SS, Xicola RM, Llor X, Ellis NA. Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. *Cancer Causes Control* 2014;25:561-70 3978221.
350. Randell RL, Long MD, Cook SF, Wrennall CE, Chen W, Martin CF, Anton K, **Sandler RS**, Kappelman MD. Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). *Inflamm Bowel Dis* 2014;20:541-4 4112538.
351. Santoro MA, Andres SF, Galanko JA, **Sandler RS**, Keku TO, Lund PK. Reduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev* 2014;23:2093-100 4201381.
352. Steck SE, Butler LM, Keku T, Antwi S, Galanko J, **Sandler RS**, Hu JJ. Nucleotide excision repair gene polymorphisms, meat intake and colon cancer risk. *Mutat Res Fundam Mol Mech Mutagen* 2014;762:24-31 4056032.
353. Wang H, Burnett T, Kono S, Haiman CA, Iwasaki M, Wilkens LR, Loo LW, Van Den Berg D, Kolonel LN, Henderson BE, Keku TO, **Sandler RS**, Signorello LB, Blot WJ, Newcomb PA, Pande M, Amos CI, West DW, Bezieau S, Berndt SI, Zanke BW, Hsu L, Genetics, Epidemiology of Colorectal Cancer C, Lindor NM, Haile RW, Hopper JL, Jenkins MA, Gallinger S, Casey G, Colon Cancer Family R, Stenzel SL, Schumacher FR, Peters U, Gruber SB, Colorectal Transdisciplinary S, Tsugane S, Stram DO, Le Marchand L. Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A. *Nat Commun* 2014;5:4613 4180879.
354. Wasan SK, Calderwood AH, Long MD, Kappelman MD, **Sandler RS**, Farraye FA. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. *Inflamm Bowel Dis* 2014;20:246-50
355. Busch EL, Martin C, DeWalt DA, **Sandler RS**. Functional health literacy, chemotherapy decisions, and outcomes among a colorectal cancer cohort. *Cancer Control* 2015;22:95-101
356. Long MD, Cadigan RJ, Cook SF, Haldeman K, Kuczynski K, **Sandler RS**, Martin CF, Chen W, Kappelman MD. Perceptions of patients with inflammatory bowel diseases on biobanking. *Inflamm Bowel Dis* 2015;21:132-8
357. Murphy CC, Martin CF, **Sandler RS**. Racial differences in obesity measures and risk of colorectal adenomas in a large screening population. *Nutr Cancer* 2015;67:98-104

358. Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS. Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. *Clin Gastroenterol Hepatol*. 2014 Nov 21. pii: S1542-3565(14)01711-X. doi: 10.1016/j.cgh.2014.11.020. [Epub ahead of print] PubMed PMID: 25460565.
359. Figueiredo JC, Crockett SD, Snover DC, Morris CB, McKeown-Eyssen G, Sandler RS, Ahnen DJ, Robertson DJ, Burke CA, Bresalier RS, Church JM, Church TR, Baron JA. Smoking-associated risks of conventional adenomas and serrated polyps in the colorectum. *Cancer Causes Control*. 2015 Mar;26(3):377-86. doi: 10.1007/s10552-014-0513-0. Epub 2014 Dec 24. PubMed PMID: 25537738; PubMed Central PMCID: PMC4331601.
360. Jones PD, Kappelman MD, Martin CF, Chen W, Sandler RS, Long MD. Exercise Decreases Risk of Future Active Disease in Patients with Inflammatory Bowel Disease in Remission. *Inflamm Bowel Dis*. 2015 Feb 26. [Epub ahead of print] PubMed PMID: 25723616.
361. Rogawski ET, Westreich D, Becker-Dreps S, Adair LS, Sandler RS, Sarkar R, Kattula D, Ward HD, Meshnick SR, Kang G. The Effect of Early Life Antibiotic Exposures on Diarrheal Rates Among Young Children in Vellore, India. *Pediatr Infect Dis J*. 2015 Mar 3. [Epub ahead of print] PubMed PMID: 25742244.
362. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, Ivanova A, Cole BF, Ahnen DJ, Beck GJ, Bresalier RS, Burke CA, Church TR, Cruz-Correa M, Figueiredo JC, Goodman M, Kim AS, Robertson DJ, Rothstein R, Shaikat A, Seabrook ME, Summers RW. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. *N Engl J Med*. 2015;373(16):1519-30. doi: 10.1056/NEJMoa1500409. PubMed PMID: 26465985
363. Rogawski ET, Westreich DJ, Adair LS, Becker-Dreps S, Sandler RS, Sarkar R, Kattula D, Ward HD, Meshnick S, Kang G. Early Life Antibiotic Exposure Is Not Associated with Growth in Young Children of Vellore, India. *J Pediatr*. 2015. doi: 10.1016/j.jpeds.2015.08.015. PubMed PMID: 26372535
364. Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. *J Clin Gastroenterol*. 2015. doi: 10.1097/MCG.0000000000000421. PubMed PMID: 26485106
365. Peery AF, Sandler RS, Galanko JA, Bresalier RS, Figueiredo JC, Ahnen DJ, Barry EL, Baron JA. Risk Factors for Hemorrhoids on Screening Colonoscopy. *PLoS One*. 2015;10(9):e0139100. doi: 10.1371/journal.pone.0139100. PubMed PMID: 26406337; PMCID: PMC4583402.
366. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, Lund JL, Pasricha S, Runge T, Schmidt M, Shaheen NJ, Sandler RS. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. *Gastroenterology*. 2015. doi: 10.1053/j.gastro.2015.08.045. PubMed PMID: 26327134
367. Fedirko V, Bradshaw PT, Figueiredo JC, Sandler RS, Barry EL, Ahnen DJ, Milne GL, Bresalier RS, Baron JA. Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). *Cancer Prev Res (Phila)*. 2015. doi: 10.1158/1940-6207.CAPR-15-0212. PubMed PMID: 26304466.
368. Figueiredo JC, Crockett SD, Snover DC, Morris CB, McKeown-Eyssen G, Sandler RS, Ahnen DJ, Robertson DJ, Burke CA, Bresalier RS, Church JM, Church TR, Baron JA. Smoking-associated risks of conventional adenomas and serrated polyps in the colorectum. *Cancer Causes Control*. 2015;26(3):377-86. doi: 10.1007/s10552-014-0513-0. PubMed PMID: 25537738; PMCID: PMC4331601.
369. Mack CD, Brookhart MA, Glynn RJ, Meyer AM, Carpenter WR, Sandler RS, Sturmer T. Comparative Effectiveness of Oxaliplatin Versus 5-fluorouracil in Older Adults: An Instrumental Variable Analysis. *Epidemiology*. 2015;26(5):690-9. doi: 10.1097/EDE.0000000000000355. PubMed PMID: 26196683.
370. Rogawski ET, Westreich DJ, Becker-Dreps S, Adair LS, Sandler RS, Sarkar R, Kattula D, Ward HD, Meshnick SR, Kang G. Antibiotic treatment of diarrhoea is associated with decreased time to the next diarrhoea episode among young children in Vellore, India. *Int J Epidemiol*. 2015;44(3):978-87. doi: 10.1093/ije/dyv040. PubMed PMID: 25929259; PMCID: PMC4607743.
371. Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of Fiber Is Associated With Greater Risk of Crohn's Disease Flare in a 6-Month Period. *Clin Gastroenterol Hepatol*. 2015 Dec 31. pii: S1542-3565(15)01713-9. doi: 10.1016/j.cgh.2015.12.029. [Epub ahead of print] PubMed PMID: 26748217.
372. Randell RL, Gulati AS, Cook SF, Martin CF, Chen W, Jaeger EL, Schoenborn AA, Basta PV, Dejong H, Luo J, Gallant M, Sandler RS, Long MD, Kappelman MD. Collecting Biospecimens From an Internet-Based Prospective Cohort Study of Inflammatory Bowel Disease (CCFA Partners): A Feasibility Study. *JMIR Res Protoc*. 2016 Jan 5;5(1):e3. doi: 10.2196/resprot.5171. PubMed PMID: 26732016.

373. Rogawski ET, Meshnick SR, Becker-Dreps S, Adair LS, Sandler RS, Sarkar R, Kattula D, Ward HD, Kang G, Westreich DJ. Reduction in diarrhoeal rates through interventions that prevent unnecessary antibiotic exposure early in life in an observational birth cohort. *J Epidemiol Community Health*. 2015 Nov 30. pii: jech-2015-206635. doi: 10.1136/jech-2015-206635. [Epub ahead of print] PubMed PMID: 26621194.
374. Peery AF, Martin CF, Levinson SE, Sandler RS. Colonic Diverticula Are Not Associated With an Increased Risk of Colorectal Adenomas. *Am J Gastroenterol*. 2015 Dec;110(12):1694-7. doi: 10.1038/ajg.2015.359. Epub 2015 Nov 3. PubMed PMID: 26526082.
375. Busch EL, Keku TO, Richardson DB, Cohen SM, Eberhard DA, Avery CL, Sandler RS. Evaluating markers of epithelial-mesenchymal transition to identify cancer patients at risk for metastatic disease. *Clin Exp Metastasis*. 2015 Oct 27. [Epub ahead of print] PubMed PMID: 26507436.
376. Murphy CC, Sandler RS, Grubber JM, Johnson MR, Fisher DA. Underuse and Overuse of Colonoscopy for Repeat Screening and Surveillance in the Veterans Health Administration. *Clin Gastroenterol Hepatol*. 2015 Oct 19. pii: S1542-3565(15)01404-4. doi: 10.1016/j.cgh.2015.10.008. [Epub ahead of print] PubMed PMID: 26492843.
377. Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of Fiber Is Associated With Greater Risk of Crohn's Disease Flare in a 6-Month Period. *Clin Gastroenterol Hepatol*. 2015 Dec 31. pii: S1542-3565(15)01713-9. doi: 10.1016/j.cgh.2015.12.029. [Epub ahead of print] PubMed PMID: 26748217.

Non-refereed Journals

1. Sandler RS, Drossman DA. Conservative approach to the diagnosis of the irritable bowel syndrome. *Internal Medicine for the Specialist* 1981;2:39-47.
2. Sandler RS. Fiber and colon cancer. *Internal Medicine for the Specialist* 1984;5:152-61.
3. Sandler RS. Early detection of colon cancer. *Modern Medicine* 1986;54(4):64-8.
4. Sandler RS. Breast cancer awareness. *North Carolina Medical Journal* 1987;48:499-500.
5. Sandler RS. Epidemiology of inflammatory bowel disease. *IBD News* 1989;10(2):1-3
6. Sandler RS. Epidemiology. *Current Opinion in Gastroenterology*. *Inflammatory Bowel Disease* 1990;6(4) 531-535.
7. Sandler RS. Fertility in Inflammatory Bowel Disease Patients. *Ostomy Quarterly* 1991;28:8-12.
8. Sandler RS. Risk Factors and Screening for Colorectal Cancer. In: *Cancers of the lower gastrointestinal tract*. Marks JE, Tepper JE, eds. Radiological Society of North America 1991:11-19.
9. Eisen G, Sandler RS. Epidemiology of Inflammatory Bowel Disease Update. *Progress in Inflammatory Bowel Disease*. 1994;15:1-8.
10. Sandler RS. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. *PPO updates: Principles & Practice of Oncology*. 1997;11 (6):1-14.
11. Sandler RS. Prevention of colorectal cancer. *Current Treatment Options in Gastroenterology* 1999;2:27-33.
12. Murray SC, Russo MW, Sandler RS, Kupper LL. Characterization of two-stage dependent screening strategies. *Proceedings of the Section on Statistics in Epidemiology*. American Statistical Association, 1999.
13. Sandler RS. Primary prevention of colorectal cancer. *Practical Gastroenterology* 2000;24:70-76.
14. Beavers KL, Rich MM, Sandler RS. How to evaluate clinical practice guidelines. *Evidence-based Gastroenterology* 2001;2:126-130.
15. Long M, Sandler RS. Exuslind prevented colorectal adenomas but was toxic. *Evidence-based Gastroenterology* 2006; 7:100-1
16. Sandler RS. Colorectal cancer screening in the elderly: can we stop the train? *AGA Perspectives* 2015;11:10-11.

Editorials/Commentaries/Letters

1. Sandler RS. Does aspirin reduce the risk for fatal colon cancer? *ACP Journal Club* 1992 March/April;116 (supplement 2):59.
2. Sandler RS. *Helicobacter pylori* and recurrent ulcer disease. *ACP Journal Club* 1992, July/August 117 (suppl 1):24.

3. Sandler RS, Ekblom A. Mortality and risk for colorectal cancer from ulcerative colitis. *ACP Journal Club* 1993; March/April 118 (suppl 1):53
4. Drossman DA, Sandler RS, Sartor RB. Our new president - Don W. Powell, M.D. *Gastroenterology* 1993;104:1249-1251.
5. Sandler RS. Cholecystectomy and colorectal cancer risk. *Gastroenterology* 1993;104: 286-288.
6. Sandler RS. Fecal occult blood screening for colorectal neoplasia. *ACP Journal Club* 1993; July/August 119 (supplement 2);25.
7. Sandler, RS. Who wants a healthful breakfast? *New England Journal of Medicine* 1994;330:1162 (letter).
8. Sandler RS. Aspirin use was associated with decreased risk for colorectal cancer. *ACP Journal Club* 1994;121:81
9. Sandler RS. Ligation is the best endoscopic choice for esophageal variceal bleeding. *ACP Journal club* 1996;124:11.
10. Sandler RS. First-degree relatives of patients with adenomas had an increased risk for colorectal cancer. *ACP Journal club* 1998; 129:75
11. Sandler RS. Appendectomy and ulcerative colitis. *Lancet* 1998 ;352:1797-8
12. Sandler RS. Does dietary wheat bran fiber protect against recurrent colorectal adenomas. *Evidence Based Gastroenterology* 2000;1:24.
13. Rich MM, Sandler RS. The effect of fecal occult blood screening on the incidence of colorectal cancer. *ACP Journal Club* 2001; 134 (2): 103
14. Sandler RS. Presentation of the Julius M. Friedenwald Medal to Don W. Powell, M.D. *Gastroenterology* 2001;120:1854-1859.
15. Sandler RS. Reporting Randomized Controlled Trials in Gastroenterology: The CONSORT Statement. *Gastroenterology* 2001 121: 755
16. Rich MM, Sandler RS. Are two screening tests better than one? *Evidence Based Gastroenterology* 2001;2:106-7.
17. Sandler RS. Guidelines for the gastroenterologist. *Gastroenterology* 2002;123:1426
18. Sandler RS. Aspirin prevention of colorectal cancer: more or less? *Annals of Internal Medicine* 2004, 140: 224-5
19. Sandler RS. Colonoscopy: virtual, optical or chromoscopic? *Gastroenterology* 2004, 126:641
20. Sandler RS. Calcium supplements to prevent colorectal adenomas. *American Journal of Gastroenterology* 2005;100:395-6
21. Sandler RS. Quality in gastroenterology – beyond the bell curve. *Gastroenterology*. 2005;128(5):1158
22. Sandler RS. Cybermedicine and the gastroenterologist. *Gastroenterology* 2006;130:1028.
23. Wei J, Sandler RS. The right test for colon cancer screening. *Gastrointestinal Endoscopy* 2006;63:459-60.
24. Runge MS, Sandler R. JOHN T. SESSIONS, JR.: 1922–2005. *Trans Am Clin Climatol Assoc*. 2006; 117: lxxiii–lxiv
25. Sandler RS. Realistic expectations after negative colonoscopy. *Clinical Gastroenterology and Hepatology* 2008;6:1068-9.
26. Sandler RS. Editorial: colonoscopy and colorectal cancer mortality: strong beliefs or strong facts? *Am J Gastroenterol*. 2010 Jul;105(7):1633-5. PMID: 20606662.
27. Sandler RS. Changes in Digestive Disease Week for 2011. *AGA Perspectives* 2010;6:20-1.
28. Sandler RS, Peery AF. Reply. *Gastroenterology*. 2012 Sep;143(3):e30. Epub 2012 Jul 26. PubMed PMID: 22841727.
29. Sandler RS. We should not screen African Americans earlier: the guidelines are unclear. *AGA Perspectives* 2013;9(3):5-8.

Abstracts

1. Sandler RS, Orlando RC, Bozyski EM. Failure of clinical criteria to distinguish achalasia secondary to cancer from primary achalasia. *Gastroenterology* 1980;24:715.
2. Nuzum CT, Sandler RS, Paulk HT. Thrombocytosis in Whipple's disease. *Gastroenterology* 1980;78:1229.
3. Sandler RS, Varma V, Herbst CA, Montana GS, Rudnick SA, Fowler WC. Late colonic effects of pelvic irradiation. *Gastroenterology* 1981;80:1296.

4. Wood DR, Frakes JT, Levinson SL, Kinard HB, Jackson AL, Sandler RS, Sartor RB, Wagner E, Powell DW. A prospective study of upper gastrointestinal bleeding. *Gastroenterology* 1981;80:1320.
5. Drossman DA, Sandler RS, McKee DC, Lovitz A. Prevalence of irregular bowel patterns in healthy adults. *Gastroenterology* 1981;80:1139.
6. Sandler RS, Sandler DP. Trends in death rates from primary hepatocellular carcinoma. *Hepatology* 1981;1:543.
7. Sandler RS, Flack PM, Everson RB. Limited evidence for urinary mutagen excretion in cirrhosis and other liver diseases. *Hepatology* 1981;1:543.
8. Sandler RS, Sandler DP. Expected yield from screening for cancer of the gastric remnant. *Gastroenterology* 1983;84:1295.
9. Sandler RS, Johnson MD, Holland KL. Risk of gastric cancer following gastric surgery for benign conditions. *Gastroenterology* 1983;84:1294.
10. Maule WT, Sandler RS, Baltus ME, Kendall MS, Holland KL. Cholecystectomy in diabetics. *Gastroenterology* 1984;86:1177.
11. Sandler RS, Drossman DA, Broom M, McKee DC. Bowel pattern reporting in healthy young adults. *Gastroenterology* 1985;88:1569.
12. Kittinger JW, Sandler RS, Heizer WD. Effect of single dose parenteral metoclopramide on enteral feeding tube transpyloric intubation: a double blind placebo controlled study. *Gastroenterology* 1985;88:1447.
13. Drossman DA, Sandler RS, Broom CM, McKee DC. Urgency and incontinence in people with bowel dysfunction. *Gastroenterology* 1985;88:1369.
14. Meshkinpour H, Roberts GS, Sandler R, Snape W, Oren J, Baky SH. Dextromethorphan in treatment of irritable bowel syndrome: a multicenter double blind study. *Gastroenterology* 1985;88:1501.
15. Sandler RS, Holland KL. Gastric cancer sex ratio trends. *Gastroenterology* 1985;88:1569.
16. Martin ZZ, Sandler RS, Holland KL, Carlton NM. Cholecystectomy and adenomas of the colon. *Gastroenterology* 1986;90:1535.
17. Drossman DA, Sandler RS, Broom CM. Rectal bleeding and bowel symptoms/behaviors. *Gastroenterology* 1986;90:1398.
18. Sandler RS, Sandler DP, Comstock GW. Cigarette smoking and the risk of colon cancer in women. *Gastroenterology* 1987;92:1613.
19. Provenzale D, Martin ZZ, Sandler RS, Holland KL. Colon adenomas in patients with hyperplastic polyps. *Gastroenterology* 1987;92:1582.
20. Martin ZZ, Readling RS, Sandler RS. Risk factors for heartburn and esophagitis. *Gastroenterology* 1987;92:1519.
21. Drossman DA, Sandler RS, Mitchell CM. What symptoms bring patients with irritable bowel to the doctor? *Gastroenterology* 1987;92:1374.
22. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Lowman BC, Burger AL, Cramer EM. Psychosocial factors in irritable bowel syndrome: a multivariate study. *Gastroenterology* 1987;92:1375.
23. Sandler RS, Holland KL. Smoking and inflammatory bowel disease. *Gastroenterology* 1988; 94:A398.
24. Sandler RS, DeVellis BM, Blalock SJ, Holland KL. Participation of high risk subjects in colon cancer screening. *Gastroenterology* 1988; 94:A398.
25. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. *Gastroenterology* 1988; 94:A398.
26. Provenzale D, Garrett J, Sandler RS. Colon adenomas in patients with hyperplastic polyps. *Gastroenterology* 1989;96:A401.
27. Sandler RS, Narendranathan M, Baird DD. Reproductive outcomes in women with inflammatory bowel disease. *Gastroenterology* 1990; 98:A202.
28. Wurzelmann JI, Sandler RS, McDonnell CW. Oral contraceptive use and the risk of inflammatory bowel disease. *Gastroenterology* 1991; 100:A263.
29. Sandler RS, Sandler DP, McDonnell CW, Wurzelmann JI. Childhood exposure to environmental tobacco smoke and risk of ulcerative colitis. *Gastroenterology* 1991;100:A17.
30. Sandler RS, Lyles CM, McAuliffe CA, Woosley JT, Kupper LL. Cigarette smoking and the risk of colorectal adenomas. *Gastroenterology* 1992;102:A394.
31. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. *Gastroenterology* 1992;102:A30.

32. Thompson C, Sandler R, Isaacs K, McCoy Z, Maness L, Lucier G, Hoel D. Comparative effects of omeprazole, cimetidine, and ranitidine on sister chromatic exchange frequencies in lymphocytes of healthy human subjects. *Gastroenterology* 1992;102:A178.
33. Thompson C, Sandler R, Isaacs K, Miller C, Maness L, Hoel D, Lucier G. Comparison of the effects of omeprazole, cimetidine and ranitidine on hypergastrinemia in humans and rats. *Gastroenterology* 1992;102:A177.
34. Sandler RS, Lyles CM, Peipins LA, McAuliffe CA, Woosley JT, Kupper LL. Diet and the risk of colorectal adenomas: macronutrients, cholesterol and fiber. *Gastroenterology* 1993, 104:A448
35. Eisen GM, Sandler RS. Are women with breast cancer at greater risk for colorectal cancer? *Gastroenterology* 1993;104:A397
36. Wurzelmann JI, Schreinemachers D, Sandler RS, Everson RB. Serum vitamin A and the risk of colorectal cancer. *Gastroenterology* 1993,104:A463.
37. Heizer WD, Sandler R.S, Seal E, Murray SC, Busby M, Schliebe B, Pusek S. Intestinal effects of sulfate in drinking water on normal human subjects. *Gastroenterology* 1994;106 A237.
38. Lyles CM, Sandler RS, Keku TO, Millikan RC, Murray SC, Ushen MH, Bangdiwala SI. Reproducibility and variability of rectal mucosal proliferation index using PCNA. *Gastroenterology* 1994; 106,A410.
39. Sandler RS, Pritchard M, McAuliffe CA, Bangdiwala SI. Physical activity and the risk of colorectal adenomas. *Gastroenterology* 1994;106, A437
40. Sander RS, Murray SC, Keku TO, Bangdiwala SI, Lyles CM, Millikan RC, Ulshen MH. Comparison of whole crypt dissection to PCNA immunohistochemistry to measure rectal mucosal proliferation. *Gastroenterology* 1994;106, A436.
41. Sandler RS, Lyles CM, Woosley JT. Do patients with small adenomas in the distal colon need full colonoscopy? *Gastroenterology* 1994;106, A436
42. Wurzelmann J, Godley P, Gallagher P, Sandler R. Erythrocyte fatty acids and the risk of colonic polyps. Annual GCRC Meeting, San Diego CA, February 28, 1995.
43. Eisen GM, Sandler RS, Coleman, Foxx-Orenstein A, Tarnasky P, Cotton PB. Development of a disease specific measure for health related quality of life for patients with chronic pancreatitis. *Gastroenterology* 1995;108:A12.
44. Sandler RS, Nyrén O, Ekbon A, Eisen G, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia: a population-based study. *Gastroenterology* 1995;108:A533.
45. Tseng M, Murray SC, Sandler RS, Kupper LL. Micronutrients and risk of colorectal adenomas. *American Journal of Epidemiology* 141(11)Suppl: S71, 1995.
46. Wurzelmann J, Godley P, Gallagher P, Sandler R. Erythrocyte fatty acids and the risk of colonic polyps. Annual GCRC Meeting, San Diego CA, February 28, 1995.
47. Godley PA, Campbell MK, Mohler JL, Lachappelle J, Gallagher P, Martinson F, Robertson CN, Philips J, Sandler RS. Conjugated linoleic acid as a biomarker of dietary intake: results of a pilot study.
48. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma selenium levels and the risk of colorectal cancer. *Gastroenterology* 1996;110:A585
49. Licato L, Keku TO, Sandler RS, Brenner DA. JNK and ERK kinases are activated in DMH-induced colonic tumors. *Gastroenterology* 1996;110:A551.
50. Straus WL, Eisen GM, Sandler RS, Murray SC, Wurzelmann JI, Sessions J. Race and Crohn's disease: clinical and therapeutic comparison of African-Americans and non-African Americans. Report of a multicenter survey. . *Gastroenterology* 1996;110:A1021.
51. Russo MW, Helm JF, Simpson KN, Ransohoff DF, Wurzelmann JI, Sandler RS. Weighing the benefits of and risks of low-dose aspirin in primary prevention of colorectal cancer. . *Gastroenterology* 1996;110:A36.
52. Straus WL, Eisen GM, Sandler RS, Murray SC, Wurzelmann JI, Sessions JT. Crohn's disease, health care utilization, and possible barriers to care in African American and non African Americans. . *Gastroenterology* 1996;110:A42
53. Wurzelmann JI, Godley P, Gallagher P, Murray SC, Sandler RS. Erythrocyte omega-3 fatty acids do not predict colorectal adenomas in humans. . *Gastroenterology* 1996;110:A47
54. Wurzelmann JI, Silver A, Schreinemachers, Sandler RS, Everson RB. Iron and the risk of colorectal cancer. *Gastroenterology* 1996;110:A47
55. Eisen GM, Sandler RS, Murray SC, Gottfried M. The association between gastroesophageal reflux disease and its complications with Barrett's esophagus. *Gastroenterology* 1996;110:A110

56. Eisen GM, Sandler RS, Murray SC, Gottfried M. Environmental risk factors for Barrett's esophagus. *Gastroenterology* 1996;110:A110
57. Eisen GM, Straus WL, Sandler RS, Murray SC, Wurzelmann J, Sessions JT and the Mid-Atlantic Crohn's disease study group. Health status in Crohn's disease: comparison of the rating form of IBD patient concerns in African and non-African Americans. *Gastroenterology* 1996;110:A15.
58. Helm JF, Russo MW, Simpson KN, Ransohoff DR, Sandler RS. Screening for colorectal cancer by fecal occult blood testing is cost-effective but is it affordable? *Gastroenterology* 1997;A18
59. Eisen GM, Maycon ZR, Sandler RS, Murray SC. Is obesity a risk factor for Barrett's esophagus. *Gastroenterology* 1997;A557.
60. Helm JF, Quade D, Russo MW, Simpson KN, Ransohoff DR, Sandler RS. What do we gain by screening for colorectal cancer with six tests for fecal occult blood and at what cost? *Gastroenterology* 1997;A576.
61. Keku TO, Galanko JA, Murray SC, Sandler RS. Rectal mucosal proliferation, dietary factors and risk of colorectal adenomas. *Gastroenterology* 1997; A590.
62. Sandler RS, Galanko JA, Murray SC, Helm JF, Woosley JT. Aspirin and non-steroidal anti-inflammatory agents prevent colorectal adenomas. *Gastroenterology* 1997;A650 .
63. Russo MW, Helm JF, Biddle AK, Sandler RS. Serial fecal occult blood testing detects more cancers at a lower cost. *Gastroenterology* 1997; A648.
64. Zacks SL, Sandler RS, Brown RS, Jr. Cost effectiveness of transjugular intrahepatic portosystemic shunt versus distal splenorenal shunt in the management of portal hypertension in Child's A cirrhosis. *Gastroenterology* 1997;A1422.
65. Jacobson JS , Potter JD , Fosdick L, Neugut AI , Bostick RM , Peipins L , Sandler RS , Martinez ME McPherson RS , Louis TA , and the Adenoma Study Group. Reproductive Risk Factors for Colorectal Adenomas: A Combined Analysis of Data from Four Case-Control Studies. *Cancer Epidemiology Biomarkers and Prevention*, 1997
66. Russo MW, Sandler RS, Fair JF, Johnson MW, Bunzendahl H, Brown Jr. RS. The effect of race and payer status on cost of orthotopic liver transplantation. *Transplantation* 1997A.
67. Zacks SL, Sandler RS, Rutledge R, Brown RS. Liver Disease Markedly Increases the Risk of Perioperative Death in Cholecystectomy Patients. *Hepatology*, 1997;26:179A.
68. Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Farup CE. A large national epidemiological study of constipation. *Gastroenterology* 1998;114:A44
69. Sandler RS, Stewart WR, Liberman JN, Stemhagen A, Farup CE, Woods MS. Symptom criteria for constipation subtypes in a US National epidemiological study of constipation. *Gastroenterology* 1998;114:A831
70. Sandler RS, Zorich NL, Filloon TG, Wiseman HB, Lietz DJ, Broch MH, Miday RK. A six-week randomized controlled trial of olestra or regular snack foods: Comparison of gastrointestinal symptoms in a large population. *Gastroenterology* 1998;114:A39
71. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Digestive complaints in the United States - A national survey. *Gastroenterology* 1998;114:A18
72. Keku RO, Murray SC, Rippe RA, Brenner DA, Licato LL, Woosley JT, Sandler RS. Mucosal proliferation and crypt fission in the rat colon. *Gastroenterology* 1998;114:A620
73. JF, Simpson KN, Sandler RS. Role of sigmoidoscopy and fecal occult blood testing (FOBT) in screening for colorectal cancer (CRC). *Gastroenterology* 1998;114:A18
74. Siddique RM, Farup CE, Sloan S, Stewart WF, Ricci J, Sandler RS. The prevalence of upper gastrointestinal symptoms in patients with diabetes: estimates from a population-based survey. *American Journal of Gastroenterology* 1998.
75. Shaheen NJ, Braun MH, Grimm IS, Sandler RS, Downs SM, Bacon BR. Liver biopsy versus genetic testing for the C282Y mutation: a comparison of diagnostic strategies for hereditary hemochromatosis using decision analysis. 1998;114:A1339.
76. Tseng M, DeVellis RF, Khare M, Maurer KR, Everhart JE, Sandler RS. Patterns of food intake and gallbladder disease in Mexican Americans. *Annals Epidemiology* 1998;8:134.
77. Jones JK, Sandler RS, Zorich NL. Experience with a postmarketing spontaneous reporting system for a macronutrient.

78. Helm JF, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS. A comparison of the effectiveness and economic impact of screening for colorectal cancer by single sigmoidoscopy and fecal occult blood testing (FOBT). *Gastroenterology* 1999;116:A64.
79. Shaheen NJ, Crosby MA, O'Malley MS, Murray SC, Galanko JA, Sandler RS. Clinicians' attitudes toward the performance of colorectal cancer screening measures by non-physician clinicians. *Gastroenterology* 1999;116:A2200.
80. Keku TO, Galanko JA, Mehta NP, Terse AP, Woosley JT, Lund PK, Sandler RS. IGF Axis, proliferation, apoptosis and colorectal adenoma risk. *Gastroenterology* 2000, 118:A535
81. Shaheen NP, Lawrence LB, Robertston DJ, Sandler RS. Quality of colonoscopy reporting: a process of care study. *Gastroenterology* 2000; 188:A465
82. Shaheen NP, Sandler RS, Silverman LM, Lawrence LB, Keku T, Maynard R, Martin C, Rohlf EM. Are hemochromatosis gene mutations a risk factor for colon cancer? *Gastroenterology* 2000;118: A703
83. Robertson DJ, Shaheen NJ, Sandler RS. 6-mercaptopurine is the most cost effective pharmacologic therapy for maintaining clinical remission after surgical resection for Crohn's disease. *Gastroenterology* 2000;118:A891.
84. Shaheen NJ, Lawrence LB, Bacon BR, Barton JC, Martin C, Sandler RS. Genetic discrimination in hereditary hemochromatosis. *American Journal of Gastroenterology* 2000.
85. Silverman LM, Shaheen NJ, Sandler RS, Keku TO, Lawrence LB, Martin CR, Maynard R, Rohlf EM. Hemochromatosis gene (HFE) mutations are associated with an increased risk of colon cancer. *American Journal of Human Genetics* 67 (4):17, 2000.
86. Keku TO, Martin CF, Galanko JA, Connelly AE, Woosley JT, Lund PK, Sandler RS. Decreased apoptosis in normal mucosa is associated with increased risk of colorectal adenomas. *Gastroenterology* 2001;120, A-662.
87. Shaheen NJ, Silverman LM, Lawrence LB, Rohlf EM, Buse JB, Sandler RS. Are hemochromatosis gene mutations a risk factor for type 2 diabetes? *Gastroenterology* 2001;120, A-227.
88. Rabineck L, El-Serag HB, Sandler RS. Incidence and survival of colorectal cancer in the United States: 1989-1997. *Gastroenterology* 2001;120, A-65.
89. Beavers KL, Fair JH, Sandler RS, Shrestha R. Donor morbidity associated with living donor transplantation. *Gastroenterology* 2001;120, A-26.
90. Sandborn WJ, Present DH, Isaacs KL, Wolf DG, Greenberg E, Hanauer SB, Feagan BG, Johnson T, Glanko J, Martin C, Sandler RS. Tacrolimus (FK506) For The Treatment Of Perianal and Enterocutaneous Fistulas In Patients With Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. *Gastroenterology* 2002 *Gastroenterology* 2002 122 (4):A81,
91. Kinney AY, Marshall Em, Dudley WN, Martin C, Sandler RS. Religious involvement and risk of colon cancer in blacks and whites.
92. Fisher DA, Martin C, Galenko J, Sandler RS, Provenzale D. Access to care: Colorectal cancer. *Gastroenterology* 2002;122 (4):A462,.
93. Keku TO, Millikan R, Worley K, Winkel S, Eaton A, Biscocho L, Martin C, Sandler RS. 5,10-methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and the risk of colon cancer in African Americans and whites. *Gastroenterology* 2002;122 (4):A593
94. Butler LM, Duguay Y, Millikan RC, Sinha R, Sandler RS, Buillemette C. UDP-glucuronosyltransferase 1A7 and characteristics of meat intake, a population based study of colon cancer. *AACR*.
95. Keku TO, Butler LM, Millikan RC, Sinha R, Rothman N, Worley K, Duckworth S, Sandlre RS. Microsomal Epoxide Hydrolase Polymorphisms, Polycyclic Aromatic Hydrocarbons and Colon Cancer, in a Population-based Study. *AACR*
96. Doctolero RY, Keku T, Tajima A, Martin C, Myai K, Sandler RS, Carethers JM. Influence Of Race On The Prevalence Of Microsatellite Unstable (MSI) Colorectal Cancers. *Gastroenterology* 2003;124:A-46.
97. Wei JT, Connelly A, About a JS, Galako JA, Martin C, Sandler RS. Eating frequency and colon cancer risk. *Gastroenterology* 2003;124:A-78
98. Fisher DA, Martin C, Galanko J, Sandler RS, Provenzale D. Colorectal cancer: risk factors for advanced disease. *Gastroenterology* 2003;124:A-79
99. Fisher DA, Dougherty K, Martin C, Galanko J, Sandler RS, Provenzale D. Race and colorectal cancer screening. *Gastroenterology* 2003;124:A-82
100. Wei JT, Mott LA, Baron JA, Sandler RS. HMG-CoA reductase inhibitor use and recurrence of colorectal adenomas. *Gastroenterology* 2003;124:A-241

101. Wei JT, Miller EA, Woosley JT, Martin C, Sandler RS. Quality of colon cancer pathology reporting: a process of care study. *Gastroenterology* 2003;124:A-357.
102. Miller EA, Keku TO, Martin C, Woosley JT, Lund PK, Sandler RS. The association between calcium and apoptosis in human rectal epithelium. *Gastroenterology* 2003;124:A-606.
103. Fisher DA, Allan ML, Martin C, Galanko J, Sandler RS, Provenzale D. Predictors of colorectal cancer screening behavior. *Gastroenterology* 2003;124:A-621.
104. Wei JT, Galanko JA, Martin CF, Sandler RS. Delay in seeking care for colorectal cancer. *Gastroenterology* 2003;124:A-621
105. Huang, K, Sandler RS, Millikan RC, Schroeder Andrew F. Olshan, Kari E. North, Jennifer J. Hu J Cigarette smoking, glutathione s-transferases M1 and T1, and colon cancer. *AAC R* 2004
106. Hu JJ, Doan T, Keku TO, Millikan RC, Galanko JA, Huang K, and Sandler RS. Associations between *GSTM1* and *GSTT1* Genotypes with Colon Cancer risk in African Americans and whites. *AACR* 2004
107. Fisher DA, Martin C, Galanko J, Sandler RS, Provenzale D. Comorbid illness and colorectal cancer screening. *Gastroenterology* 2004;126, A-176
108. Nguyen A, Doctolero RT, Keku T, Galanko J, Tajima A, Sandler RS, Carethers JM. Lower prevalence of detectable genomic instability in right sided colon cancers from blacks. *Gastroenterology* 2004; 126:A-197
109. Wei JT, Mott LA, Baron JA, Sandler RS. Vitamin B12 levels and recurrence of colorectal adenomas *Gastroenterology* 2004;126:A315.
110. Keku TO, Millikan RC, Galanko J, Bowen K, Hodgson E, Player JS, Easton A, Martin C, Sandler RS. PPAR Pro 12 Ala polymorphism and colon cancer risk. *Gastroenterology* 16:A-243
111. Williams RE, Hartmann KE, Sandler RS, Miller WC, Steege JF. Prevalence and characteristics of irritable bowel syndrome among women with chronic pelvic pain. *Gastroenterology* 2004, 126:A-373..
112. Keku TO, Lund PK, Galanko JA, Simmons JG, Woosley JT, Sandler RS. Sub clinical insulin resistance and colorectal adenoma risk. *Gastroenterology* 2004, 126,A-110
113. Thiny MT, Evans P, Sandler RS, Gangarosa LM. Steroid-induced osteoporosis prevention in a tertiary GI clinic: room for improvement. *Gastroenterology* 2004, 126:A-437.
114. Evans P, Thiny MT, Sandler RS, Gangarosa LM Prevalence of osteoporosis risk factors in a tertiary outpatient GI. *Gastroenterology* 2004, 126:A-317
115. Williams RE, Hartmann KE, Sandler RS, Miller WC, Steege JF. Prevalence and Characteristics of Irritable Bowel Syndrome Among Women With Chronic Pelvic Pain. Fifth Annual Women's Health Day. University of North Carolina at Chapel Hill. Chapel Hill, NC. March 17, 2004.
116. Williams RE, Hartmann KE, Sandler RS, Miller WC, Savitz LA, Steege JF. Recognition and Treatment of Irritable Bowel Syndrome Among Women With Chronic Pelvic Pain. Fifth Annual Women's Health Day. University of North Carolina at Chapel Hill. Chapel Hill, NC. March 17, 2004.
117. Bresalier, RS, Sandler RS, Bolognese J, Quan H, Oxenius B, Joseph R, Horgan K, Riddell R, Morton D, Lanas A, Baron J. A randomized trial of rofecoxib to prevent colorectal adenomas: the Approve trial. *Gastroenterology* 2005;128:A-35.
118. Shaheen NJ, Mitchell KL, Spacek M, Davis P, Galanko J, Sandler RS. Body fat distribution predicts the presence of Barrett's esophagus: a case-control study. *Gastroenterology* 2005;128:A-231.
119. Ballard GB, Galanko J, Schliebe B, Harp J, Sandler RS, Keku TO. Statin use increases the risk of adenomas. *Gastroenterology* 2005;128:A-296.
120. Eaton AM, Sandler RS, Carethers J, Millikan R, Galanko JA, Keku TO. MTHFR polymorphisms, folate and microsatellite unstable colon cancers. *Gastroenterology* 2005;128:A-297.
121. Keku TO, Ballard GB, Galanko J, Hua K, Anderson JN, Proffitt M, Sandler RS, Harp J. Plasma midkine and colorectal adenoma risk. *Gastroenterology* 2005;128:A-159.
122. Lackey L, Keku T, Simmons J, Proffitt M, Galanko J, Lund PK, Sandler RS. Local IGFBP-3 is associated with increased apoptosis and reduced colorectal adenoma risk. *Gastroenterology* 2005;128:A-642.
123. Jung B, Smith J, Doctolera RT, gervaz P, Alonso JC, Myal K, Keku T, Sandler RS, Carethers JM. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. *Gastroenterology* 2005;128:A-568.
124. Anderson JN, Massa B, Player J, Proffitt M, Galanko, JA Millikan RC, Sandler RS, Keku TO Ornithine decarboxylase polymorphism, NSAIDs, apoptosis and colorectal Adenoma. Third Annual Conference on Frontiers in Cancer Prevention Research, Seattle Washington October 16-20, 2004.

125. Connelly-Frost A, Poole C, Satia JA, Millikan RC, Kupper LL, and Sandler RS. Selenium, Apoptosis, and Colorectal Adenomas. *Epidemiology without Borders: Joint Meeting of the Society for Epidemiologic Research and the Canadian Society for Epidemiology and Biostatistics*, Toronto, Ontario, Canada, June 2005.
126. Steck, S.E., Butler, L.M., Galanko, J., Keku, T.O., Sandler, R.S., Hu, J.J. Nucleotide Excision Repair Genetic Polymorphisms, Meat Intake and Colon Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention* 2006
127. Jung B, Gomez J, Caro CM, Chau E, Keku T, Sandler RS, Carethers JM. Disruption of activin signaling components in microsatellite stable (MSS) colon cancers. *Gastroenterology* 2006;130:A-33
128. Keku TO, Galanko J, Omofoye S, Holston R, Peacock J, Barnes J, Sandler RS. IL-6, TNF-A, CRP Gene polymorphisms are associated with increased colon cancer risk in African Americans compared to whites in the North Carolina Colon Cancer Study. *Gastroenterology* 2006;130:A-54
129. Amin A, Galanko J, Martin C, Schliebe B, Sandler RS, Keku TO. Apoptosis in normal rectal mucosa predicts adenoma recurrence. *Gastroenterology* 2006;130:A-87
130. Austin G, Galanko J, Martin C, Sandler R. Moderate alcohol consumption protects against colorectal adenomas. *Gastroenterology* 2006;130:A-447.
131. Hu JJ, Keku TO, Galanko J, Velasco-Gonzalez C, Dandiel B, Sandler RS. DNA-Repair genetic variations in racial/ethnic differences in colon cancer risk. *AACR* 2007
132. Fisher DA, Yancy WS, Galanko J, Martin C, Sandler RS. The impact of obesity on colon cancer screening. *Gastroenterology* 2007;132(4) suppl:A148
133. Long M, Martin C, Sandler R. Oral contraceptive use, hormone replacement therapy and rectal cancer: a population-based study. *Gastroenterology* 2008;134(4) suppl:A60
134. Shen AJ, Burcal L, Mpande CN, Jenkins N, Randall T, Rawls JF, Sandler R, Keku TO. Characterization of mucosa-associated bacteria species in colorectal biopsies from normal mucosa of patients with and without adenomas. *Gastroenterology* 2008;134(4) suppl A132
135. Grau M, Sandler R, Baron JA. Effect of NSAID use after randomized aspirin treatment on the risk of colorectal adenoma. *Gastroenterology* 2008;134(4) suppl A148.
136. Kappelman MD, Rifas-Shiman S, Porter CQ, Ollendorf DA, Sandler RS, Finkelstein JA. Costs of treatment of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008;134(4) suppl A155.
137. Long M, Gangarosa L, Sandler R. Bone health quality improvement in a tertiary GI/hepatology clinic. *Gastroenterology* 2008;134(4) suppl A328.
138. Palmer LB, Kappelman M, Porter CQ, Sandler RS, Hayashi PH. Screening for hepatocellular carcinoma in a Medicaid cirrhotic population: Opportunities for improvement. *Gastroenterology* May 2010 (Vol. 138, Issue 5, Supplement 1, Page S-796)
139. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sorensen HT. The Association Between IBD and Venous thromboembolism in Danish children and adults: A Population-Based Case-Control Study. *Gastroenterology* May 2010 (Vol. 138, Issue 5, Supplement 1, Pages S-105-S-106).
140. Mahadevan U, Martin CR, Sandler RS, Kane SV, Dubinsky M, Lewis JD, Sandborn WJ, Sander BE. One year newborn outcomes among offspring of women with inflammatory bowel disease: The PIANO Registry. *Gastroenterology* May 2010 (Vol. 138, Issue 5, Supplement 1, Page S-106)
141. Devaraj B, Ramamoorthy S, Sandler RS, Keku TO, Lee A, Luo L, McGuire K, Cabrera BL, Miyai K, Carethers JM. Relationship of EMAST and microsatellite instability among patients with rectal cancer. *Gastroenterology*. May 2010 (Vol. 138, Issue 5, Supplement 1, Page S-862).
142. Long MD, Kappelman M, Martin C, Chen W, Anton K, Sandler RS. Risk factors for depression in the elderly inflammatory bowel disease population. *American Journal of Gastroenterology* 2012;107:S662.
143. Long M, Martin C, Sandler R, Kappelman M. Increased risk of herpes zoster among patients with inflammatory bowel disease. *American Journal of Gastroenterology* 2012;107:S653.
144. Piper M, Dellon E, Woosley J, Herfarth H, Sandler R, Long M. Microscopic colitis over time: increased incidence or increased utilization? *American Journal of Gastroenterology* 2012;107:S683
145. Randell R, Long M, Martin C, Sandler R, Chen W, Kappelman M. Patient perception of chronic illness care is associated with quality of life in inflammatory bowel disease. *American Journal of Gastroenterology* 2012;107:S686
146. Wasan S, Calderwood A, Long M, Chen W, Sandler R, Faraye F. Immunization rates and vaccine beliefs in patients with inflammatory bowel diseases: an opportunity for improvement. *American Journal of Gastroenterology* 2012;107:S667

147. Crockett SD, Martin CM, Snover, D, Sandler R, Baron J,. Differences in risk factors among those with serrated polyps, sessile serrated adenomas and conventional adenomas. *American Journal of Gastroenterology* 2014;109:S615.
148. Crockett DS, Martin CM, Snover, D, Sandler R, Baron J. Separating the wheat from the chaff: identifying sessile serrated adenomas among polyps previously read as hyperplastic. *American Journal of Gastroenterology* 2014;109:S603
149. Crockett SD, Shelvy E, Runge T, Eluri S, Martin CF, Baron J, Sandler RS. Patients with sessile serrated adenomas have a high risk of metachronous neoplasia on follow-up colonoscopy: a longitudinal analysis. *American Journal of Gastroenterology* 2015;110: S602.
150. Crockett SD, Runge T, Eluri S, Shelby E, Martin CF, BaronJ, Sandler RS. Natural history of patients with sessile serrated adenomas: a retrospective cohort study. *American Journal of Gastroenterology* 2015;110: S603

Contributions to Textbooks

1. Sandler RS. Bernstein Test. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. New York: Raven Press, 1982, pp. 49-52.
2. Sandler RS. Secretin injection test for diagnosis of gastrinoma. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. New York: Raven Press, 1982, pp. 129-32.
3. Sandler RS. Flexible sigmoidoscopy. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. New York: Raven Press, 1982, pp. 117-21.
4. Sandler RS. Rectal manometry and biofeedback for rectal incontinence. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. New York: Raven Press, 1982, pp. 83-90.
5. Drossman DA, Sandler RS, Irritable bowel syndrome: role of psychosocial factors (learned illness/stress). In: Read NW (ed), *Irritable Bowel Syndrome*. Grune and Stratton, Inc, 1985, pp.67-78.
6. Sandler RS. Bernstein Test. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. Second Edition. New York: Raven Press, 1987, pp. 55-58.
7. Sandler RS. Secretin injection test for diagnosis of gastrinoma. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. Second Edition. New York: Raven Press, 1987, pp. 133-135.
8. Sandler RS. Flexible sigmoidoscopy. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. Second Edition. New York: Raven Press, 1987, pp. 119-124.
9. Sandler RS. Rectal manometry and biofeedback for rectal incontinence. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. Second Edition. New York: Raven Press, 1987, pp. 80-89.
10. Baron JA, Sandler RS. Cigarette smoking and cancer of the large bowel. In: Wald N and Baron J. (eds), *Smoking and hormone-related disorders*. Oxford, Oxford University Press, 1990;167-180.
11. Sandler RS. Miscellaneous conditions of the stomach. In: Yamada T, et al (eds). *Textbook of Gastroenterology*, Philadelphia: J.P. Lippincott Company, 1991, pp.1398-1408
12. Sandler, RS. Irritable bowel syndrome. In: Everhart JE (ed). *Digestive Diseases in the United States: epidemiology and impact*. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH publication no. 94-1447, pp 594-612.
13. Sandler, RS. Gastric cancer. In: Everhart JE (ed). *Digestive Diseases in the United States: epidemiology and impact*. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH publication no. 94-1447, pp 181-204.
14. Godley PA, Sandler RS. Liver cancer. In: Everhart JE (ed). *Digestive Diseases in the United States: epidemiology and impact*. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH publication no. 94-1447, pp 225-246.
15. Sandler RS. Chapter 26. Miscellaneous conditions of the stomach. In: Yamada T, et al (eds). *Atlas of Gastroenterology*. Philadelphia: J.P. Lippincott Company, 1992 pp. 183-188.
16. Sandler RS. Rectal manometry and biofeedback. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. Third Edition. New York: Raven Press, 1993, 73-85.
17. Sandler RS. Bernstein Test. In: Drossman DA (ed), *Manual of Gastroenterologic Procedures*. Second Edition. New York: Raven Press, 1993;56-60.

18. Wurzelmann JI, Sandler RS. Secretin injection test for diagnosis of gastrinoma. In: Drossman DA (ed), Manual of Gastroenterologic Procedures. Third Edition. New York: Raven Press, 1993:86-88
19. Sandler RS. Flexible sigmoidoscopy. In: Drossman DA (ed), Manual of Gastroenterologic Procedures. Third Edition. New York: Raven Press, 1993:166-171.
20. Sandler RS. Epidemiology. Chapter 2. In: Targan S, Shannahan F (eds). Inflammatory Bowel Disease from Bench to Bedside. Baltimore, Williams and Wilkins, 1994, p. 5-31.
21. Sandler RS. Miscellaneous conditions of the stomach. In: Yamada T, et al (eds). Textbook of Gastroenterology. Second Edition. Philadelphia: J.P. Lippincott Company, 1995.
22. Sandler RS, Provenzale D. Outcomes Research in Gastroenterology. In: Yamada T, et al (eds). Gastroenterology Updates. 1995;1(3):1-17.
23. Sandler RS. Aspirin Prevention of Colorectal Cancer. In: Devita V, Helman S, Rosenberg S, (eds). Important Advances in Oncology 1996. Philadelphia: Lippincott-Raven, 1996:123-136.
24. Sandler RS. Colorectal Cancer. In: Johanson J. Digestive Diseases: Risk Factors and Prevention. New York: Raven Press, 1997: 235-264.
25. Sandler RS, Eisen GS. Epidemiology of Inflammatory Bowel Disease. In, Kirsner JL (ed). Inflammatory Bowel Disease, New York. WB Saunders Fifth Edition. 1999:889-112.
26. Sandler RS. Screening and Surveillance for GI Cancers. In, Kelsen D, Daly J, Kern S, Levin B, Tepper J. Principles and Practice of Gastrointestinal Oncology. Philadelphia: Lippincott Williams & Wilkins, 2002:55-66.
27. Sandler RS, Loftus E. Epidemiology of Inflammatory Bowel Disease. In, Sartor RB and Sandborn WS (ed). Kirsner's Inflammatory Bowel Diseases, Sixth Edition, New York. WB Saunders, 2004, Chapter 17, pp. 245-62.
28. Sandler RS. Foreword. In, Talley NJ, Locke GR, Saito Y. GI Epidemiology. Malden MA, Blackwell Publishing, 2007.
29. Sandler RS. Screening and Surveillance for GI Cancers. In, Kelsen D, Daly J, Kern S, Levin B, Tepper J, Cutsem EVJ. Principles and Practice of Gastrointestinal Oncology. Second Edition. Philadelphia: Lippincott Williams & Wilkins, 2008:45-54.

Book Reviews

1. Sandler RS. Review of Autrup H and Williams GM. Experimental Colon Carcinogenesis. CRC Press Inc, Boca Raton, Florida, 1983. Gastroenterology 1984;86:379.
2. Sandler RS. Review of Creasey WA. Diet and Cancer. Lea & Febinger, Philadelphia, 1985. Gastroenterology 1985;89:1207.
3. Sandler RS. Review of Rozen P, Reich CB, Winawer SJ. *Large Bowel Cancer: Policy, Prevention, Research and Treatment*, New York, Karger, 1991. American Journal Epidemiology 1992;135:955-956.
4. Sandler RS. Evidence-based Gastroenterology and Hepatology, New York, John Wiley & Sons, 2010. Gastroenterology 2011;140:1105-6.

Theses

1. Sandler RS. Prostaglandins, uteroplacental ischemia and toxemia of pregnancy. MD Thesis, Yale University School of Medicine, New Haven, CT, 1975.
2. Sandler RS. Primary gastric lymphoma at the North Carolina Memorial Hospital from 1975-1980. MPH Thesis, University of North Carolina School of Public Health, 1982.

PRESENTATIONS

International

1. Etiology and prevention of colorectal cancer. Silver Jubilee Lecture. Medical College Hospital. Trivandrum, India, January 14, 1992.
2. Colorectal cancer epidemiology. V Danish Cancer Society Symposium. Copenhagen, Denmark, August 18, 1997.

3. A Randomized Controlled Trial Aspirin for the Prevention of Colorectal Adenomas in Patients with Previous Colorectal Cancer. International Investigators Meeting – Vioxx Prevention Study, Lisbon, Portugal, May 30, 2002
4. Chemoprevention of colorectal cancer. Advances in Gastroenterology and Hepatology. 12th Post Graduate Course. Sociedad Espanola de Patologia Digestiva. Madrid, Spain, June 12, 2005.
5. Epidemiology measures and application in GI disease. World Congress of Gastroenterology. Montreal, Canada, September 12, 2005.
6. Clinical Research Methods in Gastroenterology. Fourth Japan AGA/GRG Symposium, Fukuoka, Japan January 20, 2006.
7. Chemoprevention of Colorectal Cancer. Société Nationale Française de Gastro-Entérologie, Lyon, France, March 20, 2007
8. Getting Your Paper Published. Société Nationale Française de Gastro-Entérologie, Lyon, France, March 20, 2007.
9. Colonoscopia y colonoscopia virtual en la detecccion precoz del carcinoma colorrectal en 2007. Sociedad Espanola de Pathologia Digestiva (SPED). Advances en Gastroenerologia y Hepatologia. Madrid, June 15, 2007.
10. Chemoprevention of colorectal cancer, 2007. Semana de las enfermedades digestivas. Madrid, June 16, 2007.
11. Chemoprevention of colorectal cancer. ECOS Internacionales, 2007, Asociación Mexicana de Gastroenterología, Mexico City, August 18, 2007.
12. Measures to reduce colorectal cancer risk: does micronutrient supplementation work? United European Gastroenterology Federation. Vienna, Austria, October 21, 2008
13. Diet and Colorectal Cancer. XXXI Congreso Panamericano de Gastroenterologia. Santiago, Chile, November 14, 2008
14. Screening for Colorectal Cancer, 2008. XXXI Congreso Panamericano de Gastroneterologia. Santiago, Chile, November 14, 2008
15. Diet and Colorectal Cancer. Asociacion Puertoriquena de Gastroenterologia. San Juan, Puerto Rico, December 3, 2008
16. Curcumin Prevention of Colorectal Neoplasia. Polyp Prevention Study Group. San Juan, Puerto Rico, December 4, 2008

National

1. Risk of gastric cancer following gastric surgery for benign conditions, American Gastroenterological Association, May 1983
2. Cholecystectomy in diabetics. American Gastroenterological Association May 1984.
3. Bowel pattern reporting in healthy young adults. American Gastroenterological Association, May 1985
4. Cigarette smoking and the risk of colon cancer in women. American Gastroenterological Association, May 1987.
5. Colon adenomas in patients with hyperplastic polyps. American Gastroenterological Association, New Orleans, May 1987.
6. Smoking and inflammatory bowel disease. American Gastroenterological Association, Chicago, IL, May 1988.
7. Colon adenomas in patients with hyperplastic polyps - a prospective study. American Gastroenterological Association, Washington, DC. May 1989
8. Epidemiology of inflammatory bowel disease. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. September 18, 1989.
9. Reproductive outcomes in women with inflammatory bowel disease. American Gastroenterological Association, San Antonio, TX, May 1990.
10. Why do people get colon polyps. ASGE Interim Postgraduate Course, San Diego CA, January 1991.
11. Exposure to environmental tobacco smoke and the risk of ulcerative colitis. American Gastroenterological Association, New Orleans, LA, May 1991.
12. Oral contraceptives and the risk of inflammatory bowel disease. American Gastroenterological Association, New Orleans, LA, May 1991.
13. Epidemiologic studies of colorectal cancer - environment to gene. Medical College of Wisconsin, Milwaukee, WI, October 21, 1991

14. Prevention of colon cancer. University of Illinois, Rockford, IL, October 23, 1991.
15. Risk factors and screening for colorectal cancer. Radiological Society of North America. Chicago, December 2, 1991.
16. Digestive Disease Epidemiology Training. National Digestive Disease Advisory Board. Crystal City, Virginia, February 24, 1992.
17. Cigarette smoking, alcohol and the risk of colorectal adenomas. American Gastroenterological Association, San Francisco, May 12, 1992.
18. Prevention and screening for colorectal cancer. Tulane University Medical School, New Orleans, Louisiana, March 4, 1993.
19. Etiology of colorectal cancer: genes, food, lifestyle. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, April 17, 1993.
20. Risk factors, diagnosis and follow-up for colorectal cancer. Cape Fear Valley Medical Center Fifth Annual Cancer Center Symposium, Fayetteville, North Carolina, April 23, 1993.
21. Diet and the risk of colorectal cancer: macronutrients, cholesterol and fiber. American Gastroenterological Association, Boston, Massachusetts, May 19, 1993.
22. Screening for colorectal cancer. Duke Comprehensive Cancer Center Annual Symposium, Durham, NC, April 22, 1994.
23. Decision analysis in gastroenterology. VA Health Research and Development Awardees Conference, Washington, DC, April 25, 1994.
24. Epidemiologic studies of colorectal cancer precursors. University of Chicago Department of Medicine, Chicago, Illinois, September 9, 1994.
25. Colorectal Cancer - Molecules to populations. American Society of Clinical Oncology Fall Educational Meeting. Atlanta, Georgia, November 12, 1994.
26. Screening for colorectal cancer. Pinehurst Medical Symposium. Pinehurst, NC, March 5, 1995.
27. Chemoprevention of colorectal neoplasms. AGA Postgraduate Course. San Diego, California, May 13, 1995.
28. Strategies for a career in clinical and outcomes research. American Gastroenterological Association GI Trainee Symposium. San Diego, California, May 14, 1995.
29. Sandler RS, Nyrén O, Ekbon A, Eisen G, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia: a population-based study. American Gastroenterological Association, San Diego, May 16, 1995.
30. Screening for colorectal cancer. Current Gastroenterology. East Carolina School of Medicine. Pinehurst, N.C. September 15, 1995.
31. Epidemiologic studies of colorectal cancer precursors - preventing colorectal cancer. UCLA School of Medicine, Los Angeles, September 21, 1995.
32. Outcomes research in gastroenterology. Mayo Clinic, Rochester, Minnesota, November 15, 1995.
33. Prevention of colorectal cancer. Second Annual Southeastern Gastroenterology Symposium, Savannah Georgia; October 6, 1996.
34. Outcomes research in gastroenterology. University of Colorado, Denver, Colorado, November 22, 1996.
35. Writing clinical research grants. Academic Skills Workshop: ADHF/AGA/GRG training initiative for junior faculty in Gastroenterology. Tempe Arizona, December 13, 1996.
36. Outcomes research in gastroenterology. Medical University of South Carolina, Charleston, SC, December 19, 1996.
37. Clinical utility of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. AGA Symposium. American Gastroenterological Association. Washington, DC. May 14, 1997.
38. Chemoprevention of Colorectal Neoplasia. University of Chicago, Chicago, IL, December 15, 1997.
39. Writing clinical research grants. Academic Skills Workshop: ADHF/AGA/GRG training initiative for junior faculty. San Diego, CA, January 16, 1998.
40. Chemoprevention of Colorectal Neoplasia. Dayton Community Clinical Oncology Program. Dayton, Ohio, May 4, 1998.
41. Comparison of gastrointestinal symptoms in a large population. American Gastroenterological Association. New Orleans, LA, May 18, 1998.
42. Digestive complaints in the United States - A national survey. American Gastroenterological Association. New Orleans, LA, May 20, 1998.
43. Screening and prevention of colon cancer in high risk groups. American College of Gastroenterology, Boston, MA, October 14, 1998.

44. Prevention of Colorectal Cancer. University of Colorado Comprehensive Cancer Center, Denver, CO, February 19, 1999.
45. Epidemiologic Studies of Colon Cancer precursors. Massachusetts General Hospital, Boston, MA, February 23, 1999.
46. Prevention of Colorectal Cancer. Massachusetts General Hospital, Boston, MA, February 23, 1999.
47. Cancer Genetics: Answers to your patient's questions: colon and rectal cancer. Duke University Medical Center, April 27, 1999
48. Prevention of Colorectal Cancer. University of Cincinnati, Cincinnati, OH, February 2, 2000.
49. Primary Prevention of Colorectal Cancer. University Hospital, Cleveland, OH, March 17, 2000.
50. Primary Prevention of Colorectal Cancer. Baylor College of Medicine, Houston, TX, April 6, 2000.
51. Racial Disparities in Colorectal Cancer. Clinical Symposium. American Society for Gastrointestinal Endoscopy. San Diego, CA, May 22, 2000.
52. Prevention of Colorectal Cancer. University of Pennsylvania, Philadelphia, PA, September 27, 2000.
53. Writing clinical research grants. Academic Skills Workshop: AGA training initiative for junior faculty. Singer Island, FL, February 23, 2001
54. Chemoprevention of Colorectal Cancer. Design Considerations and Implications. GI Drugs Advisory Committee, Food and Drug Administration, Silver Spring, MD, March 19, 2002.
55. Clinician's Perspective. Joint Meeting of the GI Dugs Advisory Committee and the Drug Safety and Risk Management Subcommittee of the Advisory Committee for Pharmaceutical Science, FDA, Bethesda, MD, April 23, 2002.
56. A Randomized Controlled Trial Aspirin for the Prevention of Colorectal Adenomas in Patients with Previous Colorectal Cancer. CALBG Group Meeting Plenary Session, Washington DC, June 15, 2002.
57. Writing clinical research grants. Academic Skills Workshop: AGA training initiative for junior faculty. Sarasota, FL, September 27, 2002.
58. Epidemiologic studies of colorectal cancer precursors. Duke University. Durham, NC, January 16, 2003.
59. Prevention of colorectal cancer. University of California San Diego, San Diego, CA, April 16, 2003
60. Epidemiologic studies of colorectal cancer precursors. University of California San Diego, San Diego, CA, April 16, 2003
61. Epidemiology of IBD. Digestive Diseases Interagency Coordinating Committee. National Institutes of Health, Bethesda, MD April 30, 2003.
62. Prevention of Colorectal Cancer. Perspectives in Colorectal Cancer. Arlington, VA September 12, 2003.
63. Colorectal cancer: is it an environmental disease. American College of Gastroenterology Annual Postgraduate Course. Baltimore Maryland, October 10, 2003
64. Fifth annual Hack Distinguished Speaker, Stanford University School of Medicine, Palo Alto, CA, March 24, 2004..
65. Chemoprevention of Colorectal Cancer. 5th Annual Perspectives in Colorectal Cancer. Chicago, IL, September 10, 2004
66. Power Presentations. AGA Academic Skills Workshop, Phoenix AZ, February 27, 2005
67. Data Management. IBD Clinical Trials Course: Principles and Practice. St Petersburg, FL, March 12, 2005
68. Writing Research Grants. IBD Clinical Trials Course: Principles and Practice. St Petersburg, FL, March 12, 2005
69. Prevention of Colorectal Cancer. Multidisciplinary Management of GI Malignancies. Lineberger Cancer Center. Hilton Head, SC, March 31, 2005.
70. Fifth Annual Salmon Lectureship, Prevention of Colorectal Cancer, Vanderbilt University, Nashville TN, April 7. 2005
71. Epidemiologic Studies of Colorectal Cancer Precursors, Vanderbilt University, Nashville TN, April 7. 2005
72. Prevention and Screening for Colorectal Cancer. 29th Annual Internal Medicine Conference, University of North Carolina School of Medicine, April 13, 2005.
73. CanCORS: New directions and potential next steps. 31st regular meeting of the Board of Scientific Advisors, National Cancer Institute, Bethesda, MD, June 28, 2005.
74. Burden of digestive diseases in the US. Digestive Diseases Interagency Coordinating Committee, NIH, Bethesda, MD September 28, 2005.
75. Chemoprevention of Colorectal Cancer. AGA Clinical Congress, Hollywood Florida, December 9, 2005.
76. Oral and Poster Presentations. AGA Academic Skills Workshop. Los Angeles California, March 12, 2006.

77. Prevention of Colorectal Cancer. University of Texas Southwestern, Dallas, TX, April 26, 2006.
78. Prevention of Colorectal Cancer. Washington University School of Medicine, St. Louis, MO, October 26, 2006
79. Epidemiologic Studies of Colon Cancer Precursors, Washington University School of Medicine, St. Louis, MO, October 27, 2006
80. Prevention of Colorectal Cancer. Columbia University, New York, NY, November 1, 2006.
81. Prevention of Colorectal Cancer. Nath Lecture, Massachusetts General Hospital, January 16, 2007.
82. Prevention of Colorectal Cancer. Virginia Commonwealth University, Richmond VA, January 25, 2007.
83. Oral and Poster Presentations. AGA Academic Skills Workshop, Miami, FL, February 9, 2007
84. Why Choose a Career in Academic Medicine. AGA Academic Skills Workshop, Miami, FL, February 9, 2007.
85. The AGA Institute: Helping build your career in GI. AGA MD-PhD Student Workshop. Miami, FL, February 11, 2007
86. Colorectal Cancer Prevention, 2007. North Carolina Society of Gastroenterology, Greensboro, NC, March 24, 2007
87. National Commission on Digestive Diseases. NIDDK Center Directors Meeting. Boston, MA, March 24, 2007.
88. Prevention of Colorectal Cancer, 2007, Department of Medicine Grand Rounds, Duke University, Durham, NC, August 3, 2007.
89. Chemoprevention of colorectal cancer. Kirsner Visiting Scholar. University of Chicago, September 6, 2007.
90. Colorectal cancer prevention, 2007. Grand Rounds. University of North Carolina Department of Medicine. October 4, 2007.
91. Getting ideas for research. Clinical Scholars Curriculum. University of North Carolina. October 12, 2007.
92. Chemoprevention of colorectal cancer. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, October 17, 2007.
93. Chemoprevention of colorectal cancer. Mayo Clinic, Rochester, MN, November 9, 2007.
94. Oral and poster presentations. Academic Skills Workshop. American Gastroenterological Association. San Antonio, TX, January 25, 2008.
95. Opportunities in epidemiologic research. MD-PhD Workshop. American Gastroenterological Association. San Antonio, TX, January 26, 2008
96. Chemoprevention of Colorectal Cancer, 2008. 39th Annual Samuel D. Kushlan Visiting Professorship. Yale University School of Medicine. New Haven, CT. February 20, 2008
97. Prevention of Colorectal Cancer. Department of Medicine Grand Rounds. Yale University School of Medicine. New Haven CT. February 21, 2008..
98. Colorectal Cancer. Do health habits matter and how do patients lower risk. Clinical Congress of Gastroenterology and Hepatology, Las Vegas, NV, January 24, 2009
99. Oral Presentations. AGA Academic Skills Workshop. Phoenix, AZ March 14, 2009
100. Epidemiologic Research. AGA MD/PhD Conference. Phoenix, AZ, March 14, 2009
101. Curcumin prevention of colorectal neoplasia. Division of Cancer Prevention. National Cancer Institute. Rockville, MD, April 9, 2009.
102. Chemoprevention of colorectal cancer, 2009, Brigham and Women's Hospital, Harvard Medical School, April 23, 2009.
103. How will we address the address the crucial challenges facing our field? AGA Presidential Address. Chicago, June 1, 2009.
104. Colorectal Cancer. Do health habits matter and how do patients lower risk. 10th Annual Perspectives in Colorectal Cancer. Chicago, IL, August 6, 2009.
105. Breaking the Blueprint: the multiple pathways to success in clinical research. AGA Academic Skills Workshop, Houston, TX, March 19, 2010.
106. The oral presentation. AGA Academic Skills Workshop, Houston, TX, March 19, 2010.
107. Primary Prevention of Colorectal Cancer. Brown University Medical School, Providence, RI, April 20, 2010.
108. Chemoprevention of colorectal cancer, 2010. GI Grand Rounds. Duke University, Durham, NC, September 23, 2010.
109. Prevention of colorectal cancer. University of Illinois Chicago, Chicago, IL, March 1, 2011.

110. Epidemiologic studies of colorectal cancer. Stanford University School of Medicine, Palo Alto, CA, April 6, 2011.
111. Building a program in translational research. University of California San Diego, La Jolla, CA October 12, 2012.
112. Colonic diverticulosis – everything you believed is wrong. University of Texas Medical Branch, Galveston TX, October 20, 2012.
113. Can the Internet be used for surveillance in IBD. Epidemiologic Research in IBD: Designing a Surveillance Program for IBD in the United States. A CCFA/CDC Meeting. Philadelphia, PA, February 25, 2013.
114. Colonic diverticulosis – everything you believed is wrong. North Carolina GI Society, Pinehurst NC, March 2, 2013.
115. Risk factors for asymptomatic diverticulosis. Duke University, Durham, NC, February 16, 2016.
116. When to consider genetic testing for colorectal Cancer. North Carolina GI Society. Pinehurst, NC, February 27, 2016.
117. Risk factors for asymptomatic diverticulosis. Loyola School of Medicine, Chicago, IL, June 17, 2016.

Local (selected)

1. Risk factors for colon cancer. Second International Searle Symposium, Chapel Hill, NC, October 7, 1991.
2. Outcomes research symposium (organizer and moderator). American Gastroenterological Association and Center for Gastrointestinal Biology and Disease. Chapel Hill, NC March 8-9, 1996.
3. Prevention of Colorectal Cancer. Robert A. Ross Obstetrics and Gynecology Society. Chapel Hill, NC, October 1, 2004
4. Prevention of Colorectal Cancer, 2004. Update in Gastroenterology and Hepatology, UNC School of Medicine, May 2, 2004
5. Making Healthy Headlines: Media Science Forum for Researchers & Journalists. UNC Schools of Public Health, Medicine and Journalism & Mass Communication. Chapel Hill, NC, March 22, 2005,
6. Methods of Detecting Colorectal Cancer. Update in Gastroenterology and Hepatology: The ABCs of GI Disease. UNC Department of Medicine. Chapel Hill, NC, April 3, 2005.
7. Prevention and Screening for Colorectal Cancer. Department of Obstetrics and Gynecology Grand Rounds, University of North Carolina School of Medicine, Chapel Hill, NC, May 4, 2005. Prevention of Colorectal Malignancies: Benefits and Costs. Update in Gastroenterology and Hepatology: Advances in Diagnosis and Management. University of North Carolina, Chapel Hill, April 22, 2006
8. Chemoprevention of Colorectal Cancer, 2007. Update in Gastroenterology and Hepatology. University of North Carolina, Chapel Hill, April 14, 2007.
9. Prevention of Colorectal Cancer, 2008. Update in gastroenterology and hepatology: applying sound principles in daily practice. Department of Medicine, University of North Carolina, Chapel Hill, NC April 26, 2008. Colorectal Cancer Screening, 2009: Interpreting the new guidelines. 33rd Annual Internal Medicine Conference. UNC School of Medicine. March 20, 2009, Chapel Hill, NC
10. Screening individuals at high risk for colorectal cancer. Update in Gastroenterology, Chapel Hill, NC, April 16, 2009.
11. Oral and poster presentations. Short term medical research students. UNC School of Medicine. July 24, 2009.
12. Getting ideas for research. GI Epidemiology Conference, UNC School of Medicine, September 22, 2010.
13. Reading the medical literature: a guide for gastroenterologists. GI Pathophysiology Conference. UNC Chapel Hill, December 17, 2009.
14. Polyps and polyposis syndromes. GI Pathophysiology Conference. UNC School of Medicine, September 28, 2010.
15. Chemoprevention of colorectal neoplasia. Preventive Medicine Residents, UNC School of Medicine, Chapel Hill, NC, February 24, 2010. Chemoprevention of colorectal cancer. Update in gastroenterology and hepatology: applying sound principles in daily practice. Chapel Hill, NC April 17, 2010
16. Diagnosing and managing hereditary polyposis syndromes. Update in gastroenterology and hepatology: applying sound principles in daily practice. Chapel Hill, NC April 10, 2011
17. Medical and surgical approach to Lynch Syndrome. GI-Surgery Conference, Chapel Hill, NC, September 7, 2011.
18. Epidemiology of colorectal cancer: latest hits. UNC GI Epidemiology Conference, March 16, 2011

19. Opportunities in epidemiologic research. UNC MD-PhD Seminar, March 21, 2011
20. Writing research grant applications. Clinical Epidemiology and Research Methods/Skills" (EPID 806). Chapel Hill, January 13, 2012.
21. Hyperplastic polyposis. GI Grand Rounds. January 31, 2012
22. Improving Appropriate Use of Surveillance Colonoscopy: A Pilot Study. GI Epidemiology Conference, February 22, 2012
23. Diagnosing and managing hereditary GI cancer syndromes. North Carolina GI Society, Pinehurst, NC, March 3, 2012.
24. Colorectal cancer: how should I screen my patients for polyps and cancers. 36th Annual Internal Medicine Conference. UNC Department of Medicine. Chapel Hill, NC March 14, 2012.
25. Diagnosing and managing hereditary GI cancer syndromes. Update in Gastroenterology, Chapel Hill, April 14, 2012.
26. Getting ideas for research. EPID 804. Chapel Hill, NC, September 14, 2012
27. Building a program in translational research. University of California San Diego, La Jolla, CA October 12, 2012. GI Epidemiology Conference, October 16, 2012.
28. Desmoid tumors in FAP. GI Grand Rounds. March 5, 2013.
29. Writing grant applications: inside lessons from study section. GI Epidemiology Conference, April 10, 2013.
30. A case of familial Mediterranean fever – GI Grand Rounds, June 11, 2013.
31. Oral and poster presentations. Short Term Research Training Program. July 19, 2013.
32. Oral and poster presentations. GI Epidemiology Conference. September 11, 2013.
33. Hereditary diffuse gastric cancer. GI Grand Rounds, November 12, 2013.
34. Writing grant applications. EPID 804. January 12, 2014.
35. Risk factors for asymptomatic diverticulosis. GI Epidemiology Conference, February 3, 2016.
36. How to get your paper published. GI Epidemiology Conference, August 27, 2016.

Online presentations

Sandler RS. (16 January 2007) Prevention of colorectal cancer. The DAVE Project. Viewed 699 times (retrieved August 30, 2007)

TEACHING

Clinical Epidemiology, Medicine and Society Course, School of Medicine, University of North Carolina, Lecturer and seminar leader, 1982-92
 Cancer Epidemiology Course, Department of Epidemiology, School of Public Health, University of North Carolina, Lecturer, 1982-90
 Cancer Epidemiology Seminar Series, Department of Epidemiology, School of Public Health, University of North Carolina, Lecturer and seminar coordinator, 1982-87
 GI Systems Course, School of Medicine, University of North Carolina, Lecturer and lab instructor, 1982-2002
 Health Care Epidemiology (EPID 212) co-instructor 1997, 1999, 2000, 2001, 2002, 2003
 Clinical Scholars Core Curriculum, lecturer, 1998-2012

MASTERS STUDENTS

1984	Marissa E. Baltus	Epidemiology	Gallbladder surgery and diabetes
1984	Anne Golden	Epidemiology	Epidemiology of inflammatory bowel disease
1986	Linda G. Phillips, RN	Nursing	The relationship between uncertainty and emotional states in patients with inflammatory bowel disease
1988	M. Narendranathan, MD	Epidemiology	Male infertility in inflammatory bowel disease and fertility and fetal outcome in women with inflammatory bowel disease
1992	Jo-David Fine, MD	Epidemiology	Comparative analysis of the accuracy of our laboratory techniques for the diagnosis and sub classification of inherited epidermolysis bullosa
1994	John Wurzelmann, MD [§]	Epidemiology	Environmental risk factors for inflammatory bowel disease
1995	Glenn Eisen, MD [§]	Epidemiology	Risk factors for Barrett's esophagus
1996	Andrew Talal, MD [§]	Epidemiology	Seroprevalence and seroincidence of Norwalk virus infection among Brazilian infants and children
1996	Walter Straus, MD [§]	Epidemiology	Black white difference in Crohn's
1997	Mark Russo, MD [§]	Epidemiology	Weighing the risks and benefits of aspirin therapy for prevention in average risk men
1998	Nicholas Shaheen, MD [§]	Epidemiology	Liver biopsy versus genetic testing for the C282Y mutation: a comparison of diagnostic strategies for hereditary hemochromatosis using decision analysis
1998	Stephen Zacks, MD [§]	Epidemiology	Effect of liver disease on perioperative mortality
1999	Dickens Theodore, MD [§]	Epidemiology	The effect of vitamin supplementation on vaccine response rates in individuals with advanced liver disease
2000	Douglas Roberston, MD [§]	Epidemiology	6-mecaptopurine is the most cost-effective pharmacologic therapy for the maintenance of clinical remission after surgical resection for Crohn's disease.
2000	Peter Mannon, MD	Epidemiology	Polymorphisms in the human Y1 receptor gene and the risk of colorectal cancer: association and gene-environment interaction
2002	Melissa Rich, MD [§]	Epidemiology	Meta-analysis of helicobacter pylori eradication and gastroesophageal reflux disease
2002	Kimberly Beavers, MD [§]	Prevention	Liver transplantation for hepatocellular tumors other than hepatocellular carcinoma.
2002	Malcolm Roberts, PhD	Epidemiology	Constipation, laxative use, and colon cancer in

			North Carolina
2002	Magda Guiler, MD	Epidemiology	Physical activity, obesity and colorectal adenomas
2004	Michelle Thiny, MD [§]	Epidemiology	Corticosteroid-induced osteoporosis prevention and treatment in a tertiary GI clinic population
2004	Jeffrey Wei, MD [§]	Epidemiology	Eating frequency and colon cancer risk
2004	Allison Eaton	Epidemiology	Association among microsatellite instability, MTHFR polymorphisms, and folate intake in colon cancer
2005	Jason Conway, MD [§]	Public Health Leadership	Higher post-transplant costs and resource utilization in adult living donor liver transplant recipients compared to deceased donor liver transplant recipients
2006	Shannon Vish, MD [§]	Epidemiology	No evidence for an association between cytokines and weight loss during combination antiviral therapy for hepatitis C
2006	Spencer Dorn, MD [§]	Epidemiology	Bone health quality initiative and the effects of estrogen containing contraceptives on disease severity in women with Crohn's disease
2008	Evan Dellon, MD [§]	Epidemiology	Diagnostic variability and immunologic features of eosinophilic esophagitis
2008	Millie Long, MD [§]	Nutrition	Oral contraceptive use, hormone replacement therapy and rectal cancer: a population based case-control study
2008	Christina Williams [§]	Nutrition	Population-based study of associations of diet with colon and rectal cancers in African Americans and Whites
2009	Lena Palmer, MD [§]	Epidemiology	Diagnostic ionizing radiation exposure in a population-based sample of children with inflammatory bowel diseases in the United States
2010	Seth Crockett, MD [§]	Epidemiology	Alcohol intake and rectal cancer: A case-control study
2010	Alfred Barritt [§]	Epidemiology	The impact of NAFLD on liver transplant outcomes
2011	Celeste Cummings, DVM	Epidemiology	The Epidemiology of Serrated and Adenomatous Polyps of the Colorectum: Results from the Diet and Health Study, Phases IV and V
2011	Anne Peery, MD [§]	Epidemiology	Diet, physical activity, constipation and the risk of asymptomatic diverticulosis
2014	Patricia Jones, MD [§]	Epidemiology	Physical activity and flares of IBD
2015	Swathi Eluri [§]	Epidemiology	TBD
2017	Bharati Kochar [§]	Epidemiology	TBD

[§] NIH Training Grant

DOCTORAL COMMITTEES

1988	Gad Rennert, MD	Epidemiology	Lung cancer in Israel, 1962-1982
1989	Stephen B. Kritchevsky	Epidemiology	Lipid, lipoprotein cholesterol, and weight change preceding the diagnosis of cancer in the Lipid Research Clinics Coronary Primary Prevention Trial
1990	H. Sharon Campbell	Health Policy	The impact of science on policy initiation: breast cancer screening in four Canadian Provinces

1992	Marci K. Campbell	Health Behavior	The impact of message tailoring on nutrition behavior change for disease prevention
1993	Lucy Peipins*§	Epidemiology	Colorectal adenomas and diet, reproductive history, and use of exogenous hormones
1995	Paul Godley, MD	Epidemiology	Biomarkers of fatty acid consumption and risk of prostatic cancer
1996	Cynthia M. Lyles	Biostatistics	The mathematical modeling of cell proliferation based on the cell cycle
1997	Marilyn Tseng*§	Epidemiology	Country of birth, food intake patterns, and gallbladder disease
1998	James Helm, MD	Epidemiology	Effectiveness and economic impact of screening for colorectal cancer
2001	Lesley Butler§	Epidemiology	Exposure to heterocyclic amines, benzo(a)pyrene, and mutagenicity from meat intake characterized by cooking methods and doneness, genetic susceptibility at the N-acetylttransferase 1 and 2 loci, and association with colon cancer in a population-based study
2002	Thelma Mielenz	Epidemiology	Association of psychosocial work characteristics with acute low back pain outcomes
2001	Dora D'Ilosova*	Epidemiology	Tea drinking and the risk of colorectal cancer
2003	Rachel Williams	Epidemiology	Irritable bowel syndrome among women with chronic pelvic pain: characteristics, treatment and post-operative outcomes.
2004	Eric Miller*	Epidemiology	The Role Of Calcium And Vitamin D In The Prevention Of Colorectal Cancer
2005	Alexandra Connelly*§	Epidemiology	Selenium and the risk of colorectal adenomas and cancer
2004	Kui Huang*	Epidemiology	Cigarette smoking, Phase II metabolic gene polymorphisms (GSTT1/GSTM1) and DNA repair gene polymorphisms (XPD, XRCC1 and XRCC3), and colon cancer in a population based case control study
2004	Leah Sansbury	Epidemiology	Use of NSAIDs and risk of colon cancer in a population based case-control study of African Americans and Whites
2007	Sangmi Kim	Epidemiology	Obesity, Inflammation and Colorectal Neoplasia
2008	Lisa Vinikoor§	Epidemiology	Transfats and risk for colorectal neoplasia
2008	Talya Salz	Health Policy	Underuse and overuse of colonoscopy among survivors of colorectal cancer
2010	Kathryn Hamilton	Physiology	Role of suppressor of cytokine signaling 3 in colorectal cancer
2011	Jennifer Lund§	Epidemiology	Examining patterns of chemotherapy use among elderly stage II and III colorectal cancer patients in the United States: An analysis using administrative data
2013	Christina Mack§	Epidemiology	Improving the validity of non-experimental comparative effectiveness research: the impact of calendar time on prescribing of novel chemotherapeutic therapies for stage III colon cancer.
2014	Adam Gracz	Physiology	Effect of Sox4 in intestinal crypt homeostasis
2014	Evan Busch	Epidemiology	Markers of epithelial-mesenchymal transition and colorectal cancer mortality: time-to-event and latent-class analyses

2015	Elizabeth Rogawski	Epidemiology	Are our favorite drugs killing the wrong bugs? The impact of antibiotic treatment on diarrhea and growth in early childhood
2015	Agostina Santoro	Physiology	Role of the IGF1R/IR system in mediating effects of IGF1, insulin and obesity on genetically damaged intestinal stem cells and risk for colorectal adenoma
2016	Caitlin Murphy**§	Epidemiology	Examining The Increasing Incidence Of Colorectal Cancer In Younger Adults

* chair, § NIH Training Grant